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ABSTRACT 
 
Transmitted founders (TF) might carry motifs that provide a phenotypic advantage that 
enables human immunodeficiency virus type-1 (HIV-1) to overcome immune barriers within 
the female genital tract. One study compared over 5000 subtype B TF and mismatched 
chronic infection envelope (env) sequences and identified two putative transmission motifs: 
Histidine at position 12 of the signal peptide (His12) and a potential N-glycan site (PNG) at 
position 413-415. Although, His12 was shown to be important for subtype B Env expression 
and viral infectivity, in our own sequence analysis subtype C variants did not carry the 
transmission motifs and the aim of this study was to determine whether His12 and PNG413 
was important for subtype C Env expression, processing, function and viral replication. 
Mutagenesis of a subtype C Env clone indicated that His12 decreased pseudovirion (PSV) 
entry efficiency without influencing Env expression, secretion and cleavage with no changes 
in the N-glycosylation profile. This suggested that His12 had a fitness cost and was thus 
selected against. However, His12 significantly enhanced the entry efficiency of infectious 
molecular clones (IMCs), suggesting that it might be beneficial for in vivo replication. The 
variation between the PSV and IMC entry of TZM-bl cells could be due to differences in assay 
conditions. On the other hand deletion of PNG413 enhanced Env expression, secretion, 
cleavage and PSV and IMC entry efficiency of TZM-bl cells. This would suggest that subtype C 
TFs carrying a PNG at 413-413 would have lower viral replicative capacity due to poor 
expression and processing of Env. The benefit of this phenotype on HIV-1 subtype C 
transmission needs to be further investigated. Unfortunately, PSV and IMC entry of TZM-bl 
cells could not be confirmed by IMC replication in peripheral blood monocytes because the 
clones could not replicate to measurable levels in these cells over the culture period. Overall, 
this study has shown that amino acid residues at positions 12 and 415 do play a role in 
modulating Env processing and function however the actual mechanism by which these 
polymorphisms impact viral fitness most likely differ to that of subtype B, explaining why 
His12 is absent and PNG413 is present in subtype C TFs. 
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SUMMARY 
 
It has been reported that in approximately 80% of HIV-1 transmission cases, clinical infection 
is established by a single variant, the transmitted founder (TF). These authors suggested that 
TFs might carry phenotypes advantageous for transmission. A study which analysed over 5000 
env sequences of TFs and chronic from subtype B variants circulating in the USA and identified 
two robust potential transmission motifs: one in the signal peptide and another site that 
coincided with a potential N-glycosylation site (PNG) at position 413-415 of Envelope (Env), 
the glycoprotein responsible for binding to host receptors and mediating entry into target 
cells. Subtype B TFs carried a histidine at position 12 (His12) of the signal peptide of Env (Env-
SP) and lacked a PNG at position 413-415 (PNG413). Two follow-up studies suggested that 
His12 increased expression levels of Env and thus infectivity. An increase in Env expression 
has been previously associated with an alteration in the N-glycosylation profile of Env, such 
that predominantly high mannose glycoforms are added. These changes in N-glycosylation on 
Env could alter the binding between Env and host receptors which could then facilitate 
transmission. However, in subtype C Env, a Glutamine was the preferred amino acid at 
position 12 (Q12) and PNG413 was present. This suggested that subtype C TF might not be 
under the same selective pressure as subtype B variants during transmission. In this study, a 
subtype C TF variant was mutated by site-directed mutagenesis to resemble a subtype B 
transmitted variant: The Glutamine in the Env-SP was changed to either a Histidine (Q12H) or 
Alanine at position 12 (Q12A) and the PNG at 413 was deleted by changing the Threonine at 
415 to Isoleucine (T415I). Env expression, secretion, cleavage and N-glycosylation of the 
mutants were compared to wild-type (WT) by measuring cell-associated gp160 and gp140 or 
gp140 and gp120 secreted into the culture medium by Western blotting. Pseudovirus (PSV) 
and infectious molecular clones (IMC) generated by yeast homologous recombination and 
that carried WT or mutated Env were used to compare Env entry efficiency of TZM-bl cells by 
luciferase reporter assay. Western blots showed that after transient transfection of HEK 293T 
cells, there was no significant increase in expression or secretion of Q12H. When Glutamine 
was replaced with another neutral amino acid, there was also no change in expression or 
secretion, suggesting that changes in amino acids at this site was not influencing retention of 
Env within the endoplasmic reticulum (ER) as previously suggested. Env is highly glycosylated 
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and it has been suggested that changes in ER retention influenced the level of gp160 
mannosylation. When gp140 N-glycosylation was compared using endoglycosidase digestion, 
there was no difference in mannosylation of Q12H and Q12A relative to WT, indicating that 
Env-SP mutations were not influencing processing within the ER. This was expected as 
expression and secretion were also not affected. However, Q12A showed a 2-fold decrease 
in gp140 cleavage relative to WT although this did not reach significance. This could indicate 
that a small non-polar amino acid at position 12 within the signal peptide influenced gp160 
cleavage in the trans-Golgi without altering ER-associated processing and trafficking to the 
plasma membrane. Alternatively, gp140 could be cleaved and processed differently 
compared to gp160 and thus cleavage of gp140 might not represent that of full-length Env. 
As we were unable to detect cell-associated gp120 we could not confirm cleavage differences 
between Q12H and Q12A with WT.  
 
On the other hand, the T415I mutant showed a significant rise in Env expression, secretion 
and gp140 cleavage compared to WT. This suggested that either an N-glycan at position 413 
or the presence of a Threonine at positon 415 was important for Env processing. Changes in 
Env post-translational processing could be very important for the production and trafficking 
of native trimers to the cell surface, altering incorporation of functional Env and thus viral 
infectivity. When PSVs, normalised to 250ng/ml p24 infected TZM-bl cells, Q12H and Q12A 
had significantly lower entry efficiency than WT whereas T415I entered the reporter cell line 
with significantly better competency. Therefore, T415I higher expression, secretion and 
cleavage could have enhanced entry efficiency by increasing the number of functional Env 
incorporated into PSVs. Similarly, the decreased cleavage of Q12H and Q12A might have 
lowered PSV entry efficiency by the incorporation of more non-functional gp160. As PSV entry 
efficiency might not mimic that of viruses able to undergo multiple rounds of infection, TZM-
bl cells were also infected with chimeric IMCs. All IMC mutants had greater entry efficiency 
than WT, although only that of Q12H and Q12A reached significance. Data of T415I described 
a potential pathway of how changes at this site increased cell-associated levels which led to 
enhanced trafficking so that more cleaved, functional trimers were incorporated into both 
PSVs and IMCs. However, the entry efficiency of Q12H and Q12A differed when PSVs and IMCs 
were compared. A potential reason for this discrepancy could be experimental. To determine 
whether this difference could be due to the limitation of the TZM-bl cell line to accurately 
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reflect in vivo infection, IMCs were replicated in PBMCs from 2 donors.  However, only the 
positive control, pNL4 and the signal peptide mutant, Q12A showed detectable virus titres 
after p24 ELISA on days 7, 10 and 14. Therefore a comparison between entry efficiency in the 
TZM-bl cell line versus replication in donor PBMCs could not be made.  
 
Irrespective of differences between PSVs and IMCs for the signal peptide mutants, our 
findings did not support those of the previous studies.  These authors reported that His12 was 
required for increased subtype B TF Env expression, incorporation and PSV/IMC infectivity 
confirming its role as a transmission motif. Our findings suggest that unlike the Histidine at 
position 12 of subtype B TF Env signal peptides, this amino acid is not involved in subtype C 
expression, secretion and N-glycosylation. However, the absence of the PNG413 which led to 
increased viral entry of the subtype C TF variant, suggests that this motif may play a role in 
transmission. However, it is unclear why subtype C TFs would carry a PNG at position 413 
unless low Env expression is an advantage during transmission. Taken together, Env 
transmission motifs of subtype C HIV-1 might differ from that of subtype B, suggesting that 
vaccines that protect against one subtype might not protect against another. Furthermore, 
immune pressure might drive the loss or gain of transmission motifs which might alter viral 
fitness and impact disease progression of some individuals. 
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CHAPTER 1: BACKGROUND AND LITERATURE REVIEW 
 
1.1 Introduction 
Identified over 30 years ago1, human immunodeficiency virus type-1 (HIV-1) has been 
extensively characterised with emphasis on uncovering virological traits which contribute to 
its success in overcoming the protection strategies of the host cell. The major challenge in the 
design of a potential vaccine is the high degree of genetic diversity that exists between HIV-1 
variants, leading to the classification of HIV-1 into at least 9 different subtypes. Subtype B is 
the most prevalent in Northern America and Europe while subtype C accounts for more than 
60% of infections globally2,3. The high genetic diversity of HIV-1 circulating globally, suggests 
that a vaccine against one subtype is unlikely to prevent infection by another.   
 
Recently, however it has been shown that despite the high genetic diversity within the donor4 
in the majority of transmission cases only a single virus, termed the transmitted founder (TF), 
leads to productive, clinical infection5. This genetic bottleneck at transmission has suggested 
that TFs carries a transmission motif that provides a selective advantage over other variants 
during transmission6,7. The most likely candidate protein to carry this signature8 would be env 
encoding the viral Envelope (Env) as this glycoprotein mediates the initial contact between 
the virus and target cells9–11. However, this does not exclude the possibility of other viral 
proteins contributing to the genetic bottleneck during HIV transmission. 
 
Studies aimed at revealing the potential transmission signatures within Env and the 
underlying molecular events8,12,13, particularly at the mucosal surface, have been underway 
for over a decade now, with the aim of bringing researchers closer to uncovering the genetic 
composition of TFs5,14  that will ultimately inform vaccine design.   
 
So far, TFs of subtypes A and C have been shown to carry Envs with shorter variable loop (V-
loop) length, have reduced potential N-glycosylation sites (PNGS) and increased susceptibility 
to neutralizing antibodies15. Extensive sequence analysis of subtype B env identified two 
potential transmission motifs: a PNG at position 413-415 and a single amino acid at position 
12 of the signal peptide. PNG415 was identified to be involved in neutralization sensitivity and 
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under-represented in subtype B TFs8. The same authors also identified that the signal peptide 
of TF Envs was enriched for positively charged, basic amino-acids commonly Histidine (H) or 
alternatively Arginine (R) at position 12. The fact that these two polymorphisms differ 
between TFs and variants at chronic stages of infection suggests that it may play a role in HIV 
transmission and potentially Env function and/or infectivity. This review will focus on the role 
of Env and particularly its signal peptide and N-glycosylation, in HIV transmission and 
pathogenesis.  
 
1.2 Diversity, genome organisation, life cycle and tropism of HIV 
HIV-1 can be classified into 4 phylogenetic groups namely M, N, O and P. Of these, M resulted 
in the pandemic spread of the virus resulting in the emergence of the virus as nine distinct 
subtypes (A, B, C, D, E, F, G, H, and K). Particular subtypes were later found to be localised 
within certain regions of the world, with subtype C dominating 50% of all infections in sub-
Saharan Africa and subtypes F, H, J and K only accounting for 1% of infections worldwide16,17. 
 
It is estimated that an average of 10.3x109 virions can be produced per day and that 2.6 days 
are required for a newly released virion to infect another cell and cause the release of a new 
population of viral particles18. The life-cycle of HIV has a half-life of 1.6 days in productively 
infected cells18 and involves a series of steps that include the delivery of two copies of the 
viral single-stranded RNA (ssRNA) into host cells19. Upon release of the ssRNA into the cell, 
the 9.7 kilobase (kb) viral genome is converted into complimentary DNA (cDNA) by the viral 
enzyme, reverse transcriptase (RT) before it is integrated into the host chromosomal DNA by 
the viral integrase. The viral genes (of which there are nine) are then transcribed into 
messenger RNA (mRNA) followed by synthesis of all the structural and accessory viral proteins 
(Figure 1.1)20. HIV has a total of six accessory proteins, namely Vif, Vpr, Tat, Rev, Vpu and Nef, 
that function as trans-activators and regulators of gene expression21. 
 
The three structural proteins, Gag, Pol and Env19 are crucial for the assembly of infectious 
particles. The pol gene encodes the protease, RT and integrase. The protease is required for 
the proteolytic processing of polyprotein precursors into mature functional proteins22,23. The 
gag gene encodes the polyprotein Gag-p5524,25 which is cleaved into: 1) the matrix protein 
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(p17) that associates with the host membrane and initiates the formation of budding  viral 
particles26; 2) the capsid protein (p24) that encloses the viral genome and is important in 
assembly of infectious viral particles27; 3) a protein, p6, that mediates incorporation of the 
accessory protein, Vpr into budding viral particles28 and 4) the nucleocapsid (p7) that is 
important for viral RNA transport and packaging as well as ensuring efficient reverse 
transcription and viral infectivity29,30. 
 
 
 
Figure 1.1: HIV-1 structure and life cycle. (A) The Env transmembrane unit (gp41) and surface unit (gp120), the 
capsid, matrix, nucleocapsid and the viral genome are shown31. Picture based on Robinson, 2002. (B) Steps 
involved in the life cycle of HIV: after dual-binding of the incoming mature virus particle to CD4 and a chemokine 
co-receptor on target cells, the viral RNA genome is released into the host cell and is reverse transcribed into 
cDNA. The viral cDNA then integrates into the host genome. mRNA transcripts of the viral genes are then 
transported to the cytoplasm where they are translated. Finally, assembly and budding of the viral particle is 
initiated and these immature particles undergo maturation32. 
 
The env gene encodes a 160 kDa polyprotein, a precursor to the surface subunit, gp120 and 
the transmembrane subunit, gp41. These subunits interact non-covalently to form a trimer of 
heterodimers that make up the mature Env on the surface of the virus (Figure 1.1A)33,34. Env 
is crucial for mediating the initial steps of viral replication in T lymphocytes, i.e. binding to the 
CD4 receptor and host cell co-receptor and fusion of viral and host cell membranes 35,36. Env 
determines viral tropism by recognising host cell-surface receptor, CD4, together with either 
CCR5 and/or CXCR4 chemokine receptors21. Virus strains that only infect via CCR5 co-
receptors are termed R5-variants whilst those which only infect via CXCR4 are termed X4-
A B 
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variants. Dual tropism has also been observed where Env is able to mediate infection by 
binding to both CCR5 and CXCR437,38. Gp120 has been shown to interact with other co-
receptors such as CCR3 and CX3CR136, however CCR5 and CXCR4 have been identified as the 
major co-receptors involved in transmission, as inhibitors which block interactions by these 
co-receptors with gp120 also prevent HIV infection36. Furthermore, individuals homozygous 
for the ccr5Δ32 polymorphism are resistant to infection by R5 tropic HIV39. 
                                    
The dual-binding of gp120 to CD4 and CCR5 or CXCR4, causes a conformational change in 
gp120 allowing gp41, which has a rod-like structure, to penetrate the cell membrane of the 
target cell enabling membrane fusion, viral entry ad productive infection10,11. On the other 
hand, dendritic cells (DCs) present in mucosal tissues and form the first line of defence against 
pathogens, transport the virus to HIV-permissive cells40,41. Immature DCs have lower levels of 
CD4 and CCR5 expression when compared to T-lymphocytes42 but express high levels of 
dendritic cell–specific ICAM grabbing non integrin (DC-SIGN) receptor on their surface that 
binds gp120 without leading to viral entry. Instead, DC-SIGN-gp120 interactions are stable 
enough for DC migration to transport HIV-1 from the genital tract mucosa to the lymph nodes 
leading to trans-infection of T-lymphocytes and systemic distribution of the virus43,44. 
 
1.3 Structure and function of gp120  
Gp120 consists of variable loops (V1-V5) and constant domains (C1-C5)45,46. Following 
cleavage, gp120 and gp41, interact non-covalently and are assembled in a trimeric complex47. 
The gp120 and gp41 interactive region is made up of a 7-stranded β-sandwich and the termini 
of gp120 anchor the surface subunit in the viral spike48,49. There are a number of highly 
conserved cysteine residues positioned throughout gp120 and gp41 that form intramolecular 
bonds important for Env trimer structure50. The cysteine residues within gp41 are sites of 
palmitoylation that ensure trafficking of Env trimers to lipid rafts for incorporation within viral 
particles. However, as not all Envs carry Cysteines within gp41 cytoplasmic tails, they are not 
essential for HIV infectivity51.  
 
Understanding the three-dimensional structure of Env can help identify mechanisms of 
function and regions ideal for vaccine design. A number of studies have investigated the 
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crystal structure of gp120 and gp41 as separate subunits, monomers and trimers either alone 
or complexed with receptors, ligands or inhibitors35,49,52–57. The crystal structure of gp120 
(Figure 1.2A) shows the organization of gp120 into inner (in orange) and outer (in blue) 
domains that form the CD4 receptor binding site (in red) at their interface. C1, C3 and C4 of 
gp120 bind CD4 whilst the variable domains have no known direct role in interactions with 
the CD4 receptor58–60. A 4-stranded β-sheet subdomain termed the bridging sheet (in green) 
is composed of two β-strands from the outer domain and the V1/V2 stem from the inner 
domain. The bridging sheet is formed as a consequence of CD4 binding, by the rearrangement 
of the two pairs of double stranded β sheets, one from the inner and one from the outer 
domain35,46. The formation of this bridging sheet reveals a previously concealed co-receptor 
binding site (for dual-binding) and the gp41 transmembrane stalk61. The gp120 and gp41 
themselves interact via the 7 β-strands of the inner domain and the extended N/C-termini62.  
 
 
       
 
Figure 1.2: The core structure of HIV-1 Envelope glycoproteins, gp120 and gp41. (A) Gp120 on the surface of 
the virus membrane in the CD4-bound conformation. The ribbon diagram illustrates the hypervariable or V-loops 
contained within gp120 that can be modified during the course of infection to optimise utilization of CCR5 
receptors and enhance resistance against neutralizing antibodies produced in the infected host. The antigenic 
regions and CD4 receptor binding site (in red) are also indicated here. Taken from Guttman et al. 2012. (B) A 
schematic representation of HIV gp120 variable and constant domains. Gp120 carries an array of N-glycans (
high oligomannose or  hybrid or complex and  unknown) believed to shield antigenic epitopes from 
neutralizing antibodies. Adapted from McCaffrey et al. 2003 and Leonard et al. 1990.  
 
A B 
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The crystal structure of gp41 indicated that the conformational changes induced by gp120 
binding to CCR5 triggered the folding of gp41 into a six helical bundle structure that 
juxtaposes host cell and viral membranes. The fusion peptide then interacts with the plasma 
membrane, creating a fusion pore which is enlarged by the membrane proximal region 
(MPER), and allowing membrane fusion63,64 
 
The sequence and structural changes in the hypervariable loops of the HIV-1 gp120 proteins 
have been the subject of a number of studies15,62,65,66. It has been suggested that the V2 loop 
contains a signal tripeptide Leucine (L)-Aspartate (D)-Valine (V) that is important in the 
infection of memory CD4+ T-lymphocytes and spread of HIV-1 in the gastrointestinal tract12,67 
whilst the V3 loop is important for membrane fusion68, a prominent target for neutralising 
antibodies69 and plays a role in co-receptor interactions70. Mutations in the V3 loop have been 
suggested to influence the switch from R5 to X4 tropism by altering the overall positive charge 
of this region and thus allowing for the interaction with the negatively charged CXCR4 co-
receptor71–73. The biological properties that these changes may influence such as efficiency of 
transmission and infectivity of the virus has been extensively studied, particularly in response 
to the pressure exerted by host immune responses74–76.  
 
1.4 Processing of Envelope 
Processing of the Env precursor occurs both co-translationally and at the post-translational 
level. The precursor is synthesised as gp160 monomers in the endoplasmic reticulum (ER) and 
modified by Asparagine (N)-linked glycosylation. These N-glycans are then further modified 
in the compartments of the Golgi after trimerisation and before cleavage and incorporation 
of functional trimers into virions77. Env is targeted to the rough endoplasmic reticulum (RER) 
by a signal peptide comprising 30 amino acids long with an N-terminal region containing five 
positive amino acids78. Approximately 20-35 potential N-glycosylation sites (PNGS) have been 
identified in gp16079 and N-linked glycosylation contributes to approximately 50% of the 
molecular weight of gp12058,80. N-glycosylation occurs simultaneously with translation81 along 
with O-linked glycosylation82 by membrane-bound oligosaccharyl transferases found in the 
ER83 (Figure 1.3) generating gp160 trimers carrying high mannose N-glycans. The high 
mannose residues are then modified in the Golgi network and gp160 trimers are cleaved into 
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gp120 and gp41 in the cis or medial Golgi before insertion into the plasma membrane for 
incorporation, virion assembly, maturation and budding84,85. Cleavage of gp160 trimers is 
essential for viral infectivity seeing that it releases the fusion peptide, essential for membrane 
fusion86. The mechanism of Env trimer incorporation within infectious virions is not well 
characterised however the cytoplasmic tail of gp41 and the Gag matrix is thought to play a 
role87. It has been estimated that approximately 10 Env trimers are incorporated per virion 
due to reduced Env levels within the plasma membrane because of rapid endocytosis of Env 
trimers and shedding of gp120 into the culture medium88. The potential advantage to this low 
number is possibly to limit detection by immune responses especially noting that increasing 
the number of Env spikes above a particular threshold did not lead to increased HIV 
infectivity89. 
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Figure 1.3: Schematic diagram of the overall processing and trafficking of HIV-1 Envelope. 1) During translation, 
the precursor Env (gp160) is directed to the rough endoplasmic reticulum (RER) by its signal peptide (SP) found 
on the N-terminal domain of the nascent polypeptide. 2) The SP is cleaved by a signal peptidase co-translationally 
and Env is then released into the lumen of the RER. 3) During folding, precursor N-glycan structures are added, 
followed by mannose addition and and trimerization. 4) The Env then translocates through the various 
compartments of the Golgi where its glycosylation is further modified in a sequence of reactions. 5) The fully 
glycosylated and trimerized Env is then cleaved by host cell proteases within the trans-Golgi network into gp120 
and gp41 subunits or inside trans-Golgi-derived secretory vesicles. The surface unit, gp120, and transmembrane 
unit, gp41 associate via non-covalent interactions. 6) The cleaved trimers accumulate at the cell membrane of 
the host cell where they await the other viral proteins for assembly and release of the virus particle85,90–92.
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1.4.1 Role of the signal peptide in directing processing of Env  
 Overview of the mammalian secretion system 
The eukaryotic secretion system involves the translocation of proteins into a specialised 
intracellular organelle, the ER and then to the cell surface via the Golgi apparatus93. In the ER, 
proteins can be modified either during (co-translationally) or after synthesis (post-
translationally). Modifications include: proline hydroxylation, N-linked glycosylation and/or 
disulphide bond formation for stability upon release into the extracellular environment94. 
Misdirected or misfolded proteins on the other hand are secreted to the cytosol (away from 
the ER) where they are degraded94,95. 
 
 Structure and function of the signal peptide in mammalian secretion systems 
Signal peptides (SPs) are usually situated at the N-terminal end of nascent secretory and 
membrane proteins96. SPs function to direct the transport of proteins destined for the plasma 
membrane to the ER97 as well as other post-targeting functions98.  It is commonly comprised 
of 16-30 amino acids and is necessary in the recognition of the nascent protein by signal 
recognition protein (SRP). It has a tripartite structure (Figure 1.4) consisting of a hydrophilic 
and usually positively charged N-terminal region, a central hydrophobic region important for 
targeting to and insertion into the ER membrane99, and a C-terminal region with the cleavage 
site for the signal peptidase (SPase)100. For cleavage to occur the -1 position must contain an 
amino acid residue with a short side chain whilst position -3 should not contain any charged 
amino acids99. The SP is cleaved in the ER by the SPase, made up of five polypeptides forming 
a hetero-oligomeric complex, following transport to the ER. Even with these common 
characteristics, signal peptides do not share any sequence similarity and may differ in length 
as well101 with the N-terminal region displaying the greatest diversity in amino acid 
composition102. 
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Figure 1.4: Tripartite structure of the N-terminal signal sequence found on nascent secretory and membrane 
proteins. The signal sequence is comprised of a hydrophilic and usually positively charged N-terminal region (n-
region), a central hydrophobic region (h-region) and a C-terminal region with the cleavage site for the signal 
peptidase (c-region)98. 
 
Upon arrival at the ER, the signal sequence inserts into the membrane in a loop-like fashion 
where the N-terminal portion remains on the cytosolic side and the C-terminal part emerging 
into the lumen of the ER103–105. The signal sequence is usually rapidly cleaved off co-
translationally in the ER lumen. However in some instances where the signal sequence 
influences the timing of folding and association with chaperones in the ER, cleavage occurs 
several minutes after the appearance of the protein in the ER106. This slow cleavage of the 
signal sequence has thus been identified as a key determinant for the retention of certain 
proteins in the ER during the folding pathway107. 
 
Short signal sequences function only in the targeting of nascent proteins for insertion into the 
ER membrane and can be rapidly degraded. Good examples of these are the signal sequences 
of serum albumin and vesicular stomatitis virus G-protein (VSV‑G), considered as minimal 
signal sequences. SPs have demonstrated post-targeting functions as well by functioning 
either from within the membrane, as a released peptide or as a fragment generated by intra-
membrane proteolysis. These are structurally different from conventional signal sequences 
as they have extended N-terminal regions or two hydrophobic regions. So far, all examples of 
stably membrane-integrated signal peptides are of viral origin and are derived from 
precursors of viral envelope glycoproteins98.  
 
 Mechanism of mammalian secretory pathways 
Entry into the ER begins with the recognition of the protein's N-terminal signal sequence by 
SRP108 which consists of six polypeptides109 and a small cytoplasmic RNA (7sL RNA) 110. 
Interaction between the signal sequence and SRP determines the efficiency with which the 
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nascent polypeptide enters the secretory pathway111,112. The ribosome-nascent polypeptide 
chain-SRP complex binds to the ER membrane via the SRP receptor on the surface of the 
ER113,114 (Figure 1.5). The SRP acts to inhibit further elongation of the nascent polypeptide 
chain until binding to the SRP receptor occurs. Binding to the receptor releases the SRP from 
both the ribosome and the signal sequence of the growing polypeptide chain115,116.  The Sec61 
translocon is a heterotrimeric protein complex consisting of Sec61α, Sec61β and Sec61γ 
chains117. It acts as a proteinaceous pore in the membrane which accepts the ribosome-
nascent polypeptide complex. This allows for the translocation of the chain across the 
membrane and into the ER94 and elongation continues118. This process is coupled to the 
hydrolysis of GTP119. SRP and the Sec61 translocon are also potential targets for regulation in 
translocation to the ER as both recognise the signal sequence in the growing polypeptide 
chain120. Folding of the polypeptide takes place in the lumen of the ER and as folding occurs, 
exposure to modifying enzymes create a temporal relationship between folding and post-
translational modifications94.  
 
 
Figure 1.5: Co-translational translocation of proteins into the ER. Translocation into the ER occurs with the 
recognition of the nascent signal peptide (SP) as it emerges from the ribosome and is recognised by the signal 
recognition protein (SRP). Translation halts temporarily as the ribosome-SP-SRP complex is directed to the ER 
membrane where it is recognised by the SRP receptor. The ribosome then binds the Sec61 translocon pore for 
the movement of the nascent polypeptide into the ER lumen. Upon recognition of the cleavage site, the signal 
peptidase cleaves the signal peptide and the nascent polypetide is then bound by molecular chaperones (not 
shown) in order for folding and glycosylation to occur. Illustration accessed from: http://mol-
biol4masters.masters.grkraj.org/html/Co_and_Post_Translational_Events3-Eukaryotic_System.htm  
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 Secretion of Env 
Whilst still inside the ER lumen, the precursor gp160 associates with lectin chaperones that 
assist in its folding as it translocates through the ER on its way to the Golgi apparatus. These 
chaperones, calnexin (a type I membrane protein) and calreticulin (soluble in the ER), 
associate with the N-glycosylated gp160121  and are involved in the retention of misfolded or 
unfolded glycoproteins in the ER122. Other chaperones include the ER resident protein 57 
(Erp57), a soluble thiol-disulfide oxidoreductase, which associates with calnexin and 
calreticulin in order to introduce disulfide bonds in the folding glycoprotein123. The oxidising 
environment of the ER lumen itself also facilitates the conversion of the cysteine residues in 
the glycoprotein into disufide bonds124. Binding immunoglobulin protein (BiP), is a chaperone 
also residing in the ER lumen that seals the Sec61 translocon on the luminal side of the ER and 
is responsible for recognising exposed regions of unfolded proteins as well as targeting them 
for degradation125. 
 
 Timing of signal peptide cleavage is crucial for Env structure and function 
The Env signal peptide (Env-SP) is removed post-translationally107 by ER membrane-bound 
peptidases. Folding of gp160 is a requirement for cleavage of the Env-SP as lack of disulfide 
bonds leads to loss of signal peptide cleavage107,126. Once properly folded, trimerised and 
partially glycosylated, precursor gp160 moves to the translational ER (tER) where it is 
packaged into vesicular tubular complexes (VTCs) which then fuse to the cis-Golgi. The 
precursor gp160 contained within these VTCs are then transported through the stacks of the 
Golgi and enter into the trans-Golgi network (TGN) where complex sugars are added to the 
high-mannose oligosaccharide side chains86,127.  Inside the Golgi, gp160 is proteolytically 
cleaved by furin or furin-like proteases at a highly conserved Lysine (K)/N-X-K/N-N motif128,129. 
Gp160 proteolytic cleavage into gp120 and gp41 subunits can also occur in trans-Golgi-
derived (TGN) secretory vesicles130. Proteolytic processing of gp160 is an absolute 
requirement for the activation of Env fusogenic activity. After cleavage, gp120 and gp41 
remain associated via non-covalent interactions47.  
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 Functional determinants of signal peptide function 
Expression and secretion levels of protein is associated with the rate of Env-SP cleavage which 
is influenced by the presence of positively charged amino acids at the N-terminus13,107,131. The 
hydrophobic core has been suggested to be involved in the initiation of secretion132 although 
substitution of non-polar with charged amino acids did not abrogate translocation and N-
glycosylation133. On the other hand, the positively charged amino acids have been suggested 
to play a role in determining the efficiency of protein secretion132,134. Env-SP has an unusually 
high number of positively charged amino acids in the N-terminal region compared to typical 
eukaryotic SPs78,107. Env expression and secretion levels are associated with the rate of Env-
SP cleavage which is influenced by the presence of positively charged amino acids at the N-
terminus13,107,131. Sequential substitution of the positively charged residues with neutral 
amino acids was found to enhance protein expression and secretion by reducing the SP 
cleavage time and thus the time spent in the ER lumen107. The slow cleavage of the SP (and 
low secretion) is an intrinsic property of Env irrespective of the expression system102 and it 
has been suggested that the secretion block is as a result of the presence of a highly charged 
N-terminal portion of the signal sequence. As a result, this limits the transport of gp120 from 
the ER to the compartments of the Golgi107.  
 
 Role of the signal peptide in Env expression and processing 
Early research showed that the signal peptides of honey bee mellitin and murine interleukin 
3 increased efficient folding, intracellular transport, and secretion of gp120. A similar result 
was observed when the positively charged amino acids in the native gp120 signal sequence 
was replaced with neutral amino acids, highlighting the importance of the SP on Env 
processing107. SP exchange experiments suggested that when the Env-SP was replaced with a 
heterologous one, expression was altered135,136. Furthermore, deletion of the endogenous SP 
resulted in the nuclear accumulation of non-glycosylated Env as entry into the ER was 
prevented107. Changes in Env expression might lead to changes in its N-glycosylation profile 
as transfection with increased ratios of Env:backbone plasmids lead to an increase in 
mannosylation137. Slower cleavage of the Env-SP has been suggested to lead to an 
accumulation of Env in the ER84,107,124 which could lead to the production of “junk” gp160 
compromising predominantly of unprocessed oligomannose-type N-glycans138. The 
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accumulation of Env inside the ER may overwhelm the cellular machinery of the organelle139, 
potentially influencing downstream processing such as its N-glycosylation. 
 
1.4.2  N-glycosylation in the ER and compartments of the Golgi 
  N-glycosylation in mammalian cells 
Over 70% of the eukaryotic proteome is thought to be N-glycosylated and different 
glycoproteins are modified to different extents so that secreted or membrane-bound proteins 
can emerge from the Golgi with a variety of different N-linked oligosaccharides140. Within the 
ER, N-glycosylation starts with the formation of the core oligosaccharide comprising of three 
glucose (Glc), nine mannose (Man) and two N-acetylglucosamine (GlcNac) residues 
synthesized on a lipid dolichol carrier anchored in the ER membrane141,142. As the growing 
polypeptide chains are translocated into ER, the Glc3Man9GlcNac2 core oligosaccharide is  
transferred from the dolichol carrier to Asparagine residues within the sequon N-X-Threonine 
(T)/Serine (S) (where “X” is any amino acid except proline)143–145. Addition of glycans at each 
of these motifs does not always occur, as sequons are variably utilized even on the same 
protein146. It has been postulated that sequons proximal to the C termini of glycoproteins are 
unlikely to be glycosylated144,147 and that structural constraints, such as proximity to a 
disulfide bond for example, may influence sequon occupation142,145,148. ER glucosidases and 
α-mannosidase I, sequentially remove the three Glc residues in a site-specific manner along 
with a mannose residue yielding Man8GlcNAc2149. The removal of glucose residues is thought 
to be essential for proper folding and transport of proteins to the Golgi apparatus127. 
 
  Processing of high mannose core oligosaccharides in the Golgi 
Once the protein reaches the cis-Golgi compartment, mannose moieties are removed from 
Man8GlcNAc2 to give Man5GlcNAc2, the high-mannose N-glycan that is the substrate for the 
enzymes found in the compartments of the Golgi for further modifications (Figure 1.6). 
 
In the medial-Golgi, two more Man residues are removed and three GlcNAc and one fucose 
are added, giving rise to hybrid type N-glycans. Mature complex N-glycans are formed in the 
trans-Golgi with the addition of more GlcNAc moieties accompanied by other modifications 
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via the β-1,2-N-acetylglucosaminyl-transferase I (GnTI)127,150,151. Fully processed Envs that 
carry a combination of high mannose, hybrid and complex N-glycans are then transported to 
the cell membrane or shed as gp120 into the extracellular environment. 
 
 
Figure 1.6: N-linked glycosylation of Envelope.  As the protein enters the Golgi, a sequence of reactions occur 
beginning with the trimming of the conserved 14-sugar core yielding the high mannose glycoform. This is 
followed by the addition of an N-acetylglucosamine, the removal of additional mannose residues to yield hybrid 
N-glycans. Finally, terminal glycosylation occurs with the addition of three galactose and three sialic acid and/or 
fucose residues and two N-acetylglucosamines to give rise to the complex type N-glycans 150. 
 
 N-glycosylation of Envelope 
HIV-1 Env is entirely processed by the glycosylation machinery of the host cell152 and 
interaction with the spectrum of enzymatic activities present in the secretory pathway 
determines the types of glycans that will be presented on gp120 at the virion surface or as a 
recombinant protein. An “intrinsic” high-mannose patch was identified  at the surface of 
recombinant gp120 and virus-derived Envs153. Despite sequence variation, location and 
number of PNGs, the mannose patch is highly conserved over the course of infection. It can 
thus provide a stable target for vaccine strategies154 especially as it has been identified as a 
potential non-self-target for broadly neutralising antibodies (bNAbs)50,137,153,155,156. Even 
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though  glycan structures are known to act as a “shield” to protect the polypeptide chain from 
immune recognition62, some of the most potent nAb recognise the mannose patch77,157. 
 
In addition to the mannose patch found on gp120 monomers and viral-associated trimers, 
virus-associated gp120 carried more high mannose N-glycans (56-79%) than that of 
recombinant protein (29%).  When pseudovirus-associated gp120 was characterised, 98% of 
total N glycans comprised of oligomannose residues137.  A number of subsequent studies 
confirmed that the majority of Env PNGs carried oligomannose N-glycans77,158. Last year, Go 
et al. (2017) analysed the N-glycosylation of 11 trimers and identified a “consensus profile” 
where more than half of the PNGs carried the same type of N-glycosylation i.e. either high 
mannose residues or complex sugars. However, trimers were still predominantly 
mannosylated159. 
 
As mammalian N-glycosylation pathways do not usually produce clusters of oligomannose 
carbohydrates148, the apparent high mannosylation of Env might be due to variation in viral 
processing signals or cell-specific machinery. It has been proposed that the oligomannose-
type N-glycans found on gp120153 could be due to an alternative processing pathway which 
bypasses the trans-Golgi and thus the action of GnTIs137 potentially because of the 
accumulation of Env in the ER due to slow signal peptide cleavage84,107,124. Alternatively, it has 
also been suggested that high oligomannose density prevents access of endo-glycosidases to 
sites of processing, such that complex residues are not added160. This hypothesis was 
supported when virus-associated trimers were shown to carry predominantly high mannose 
residues and recombinant protein had more complex N-glycosylation153.  
 
The HEK 293T and CHO cell lines have been successfully used in the production of functional 
recombinant gp12081,137 as well as stable Env trimers161. This suggests that these cell lines 
have the functional machinery to ensure the correct processing and glycosylation of gp120 
especially noting that the N-glycosylation profiles of Env produced in PBMCs are similar to 
that expressed in HEK 293T cells. However, differences in N-glycosylation between cell lines 
have been observed156 as pseudovirus-associated gp120 are differentially N-glycosylated at 
specific positions depending on the cell line used160,162,163. Furthermore, Raska et al. (2010) 
showed that the influence of cells on Env N-glycosylation also extended to the metabolic state 
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of the cells164. These findings suggest that glycosylation of Env is determined by the structure 
of Env as well as cell-directed effects160,162,163. It is likely that optimum combinations of viral 
factors and cell-mediated processes are required to reproduce Env N-glycosylation of native 
trimers. Therefore, selection of Env clones and cell lines for the production of recombinant 
gp120 and virion-associated Env trimers for vaccine production must be carefully considered 
as Env N-glycosylation must resemble that of virus infecting CD4+ T cells to elicit broadly 
neutralising antibodies. 
 
 Significance of N-glycosylation on Env folding and retention within the ER 
It has previously been shown that heavily glycosylated proteins require N-glycans for correct 
folding and Env is no exception as N-glycosylation has been found to be crucial for the 
transport of Env from the ER to the Golgi82,165,166. N-linked oligosaccharides stabilise the 
folded domains167 and make the proteins more soluble126. They are needed for recognition 
by lectin chaperones that assist with Env folding in the ER121. When cells were treated with 
the glycosylation inhibitor tunicamycin168, misfolding of gp120 occurred169 and as a result the 
signal peptide was not removed124. The deletion of multiple N-glycosylation sites impacted 
Env folding, whereas the removal of one or two sites had no effect166. However when only 
three conserved N-glycosylation sites were removed within the gp41 domain, misfolding 
occurred which resulted in the retention of Env in the ER170. This suggests that the influence 
of N-glycosylation on protein folding might differ according to the PNG under investigation 
and/or the Env clone.  
 
N-glycans were also important for the functioning of Env as loss of certain PNGS resulted in 
increased or decreased viral infectivity171. Overall changes in Env conformation due to loss of 
N-glycans might have a domino effect on the spatial rearrangement of domains that facilitate 
and moderate interactions with host proteins such as binding to co-receptors on target 
cells171,172. Furthermore, it has been shown that the type of N-glycans also influences Env 
function with high mannose residues favouring dendritic cell interactions while lowering the 
efficiency at which virus infected TZM-bl cells173. These findings suggest that N-glycosylation 
plays a role in the function of Env that may ultimately impact transmission. 
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1.5 Env transmission motifs 
1.5.1 Genetic bottleneck associated with HIV transmission 
The genetic bottleneck during HIV transmission refers to the movement of a single variant to 
a new host from a donor infected with variants of high diversity5 (Figure 1.7). Wolinksky and 
colleagues (1992) were the first to identify that a specific subset of viruses were present 
following mother-to-infant HIV-1 transmission shortly after transmission174. After the analysis 
of the V3 loop and V4-V5 env sequences of mother-to-child transmission pairs, infant env 
sequences were found to be less variable than those found within the respective mother. 
Later, a study using a quantitative heteroduplex tracking assay provided the first evidence of 
selection during HIV-1 heterosexual transmission due to the presence of a more 
homogeneous env population in acutely HIV-1 infected subjects compared to those found in 
the donors175. Another study then showed that heterosexual transmission of subtype C HIV-
1 in discordant couples was characterised by a genetic bottleneck as only a single variant from 
a diverse donor quasispecies established productive infection176. Subsequent studies using 
single genome amplification (SGA) env amplicons revealed that in approximately 8-% of 
subtype A, subtype B, subtype C and recombinant HIV-1 infections, productive infection was 
as a result of a single infectious virus7,177–180 and initiated the search for the “transmission 
motif” thought to be found on a subset of variants - transmitted founders (TFs) – that provide 
a selective advantage during transmission7. 
 
 
Figure 1.7: HIV-1 genetic bottleneck at transmission. Despite the deposition of a swarm of genetically diverse 
HIV-1 variants in the genital tract, only a single variant, termed the transmitted founder (TF), crosses the mucosal 
barrier to initiate productive infection. 
(TF) 
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Transmission rate per coital act is as low as 1/200 to 1/2000 per coital act for male-to-female 
(MTF) transmission and female-to-male (FTM) transmissions is 1/200 to 1/10000181. These 
frequencies occur even in regions where there is a high prevalence of HIV-1 infections. This 
suggests that the genital mucosa is a formidable barrier to HIV-1 transmission. The frequency 
with which more than one virus is able to lead to productive clinical infection was found to 
increase dramatically in the presence of chronic ulcerative disease or inflammatory genital 
infections in the recipient, suggesting that disruption of the barrier might abrogate the 
selection mechanism179. TF envs have low diversity178 and are almost always R5-tropic, 
supporting the hypothesis that the viral envelope may be responsible for the selection of 
specific variants in the female genital tract14,179,182. Thus, TFs might have distinct 
characteristics that allow them to overcome the mucosal barrier as well as enhance infection 
of susceptible cells. 
 
1.5.2 Characteristics of the TF Env  
Difficulties in identifying and characterising TF Env were overcome with the advent of single 
genome amplification (SGA). SGA involves limited dilution of viral cDNA followed by two 
rounds of polymerase chain reaction (PCR) in order to ensure the presence of a single 
template molecule and prevent PCR-induced recombination183,184. This has provided 
researchers with the ability to accurately identify the TF variant and reveal distinct 
characteristics that may facilitate transmission. Genotypic characteristics of TF envs appear 
to be subtype-specific. Analysis of subtype A and C TF env sequences showed that these 
variants had shorter variable loops with fewer PNGS compared to variants isolated during 
chronic infection15,185. This was in contrast to env sequences analysed from subtype D TFs 
which, although had shorter variable loops, did not differ in the number of PNGS compared 
to chronic infection viruses186. There was no consensus on whether subtype B TF env 
sequences differed in variable loop length and PNG number compared to chronic infection 
Envs as some studies showed no difference6,187. whereas others indicated that transmission 
might select for variants with shorter Env variable loops and fewer PNGS8. Although subtype-
specific differences in variable loop length and number of PNGS may exist, the transmission 
of variants carrying gp120s with less PNGS has been consistently identified. This supports the 
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suggestion that high numbers of N-glycosylated residues accumulate over the course of 
infection to conceal conserved Env antigenic regions from antibody neutralization15,62. 
 
A common feature of TF viruses is their dependence on CCR5 co-receptors for infection of T-
lymphocytes, indicating that R5-tropism is a characteristic selected during transmission 
and/or acute infection7,65. These variants have also been found to have enhanced 
neutralization sensitivity15 although other findings have not supported this suggestion187,188. 
Initial studies found that R5 tropism was linked to macrophage-tropism175, however recent 
studies  have shown that TFs are unlikely to infect macrophages due to their low levels of CD4 
expression189,190.  
 
Dissemination of the virus into the gut-associated lymphoid tissue (GALT) results in a rapid 
depletion of the gut CD4+ cells contributing to immune dysfunction191. Migration of T-
lymphocytes to the GALT is mediated by the homing integrin, alpha-4-beta-7 (α4β7), which is  
highly expressed on CD4+ T cells of the genital mucosa192 and gut193. α4β7, mediates the 
migration of CD4+ T cells from Peyer’s patches and mesenteric lymph nodes to the lamina 
propria by binding mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expressed on 
the endothelial cells of these tissues194. α4β7 also binds to a motif identified in the V2 loop of 
gp120  identical to that of  MAdCAM-1 and is conserved across HIV subtypes A, B, C and 
D12,193,195. As HIV-1 infected CD4+ T-lymphocytes that express α4β7 with high efficiency191, 
the α4β7 binding site is conserved in the highly  variable V2 loop and substitution of this 
tripeptide resulted in a reduction in the replicative capacity of these viruses12 it was suggested 
that α4β7 may be important in HIV infection and transmission.  However, when Parrish and 
colleagues (2012) compared subtype C TF and chronic Envs they found that TF Envs did not  
utilise  α4β7, CD4 or CCR5 more efficiently suggesting that the interaction between gp120 
and α4β7 was not essential for transmission across mucosal surfaces67. 
 
Analysis of 6303 early and chronic SGA Env sequences identified potential transmission motifs 
in the signal peptide and V4 region of gp1208. A Histidine residue at position 12 [(His12) 
(position 9 according to HXB2 numbering)] within the signal peptide and the absence of a PNG 
at position 413-415 (PNG413) were identified as robust markers of TF variants8. It was 
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suggested that the presence of His12 and/or the absence of a PNG413, respectively, may 
provide an advantage during transmission. Recently, a site within Env-SP was also identified 
as a putative simian immunodeficiency virus (SIV) transmission motif, Arg9, although whether 
the actual residue aligned with His12 or an amino acid three residues upstream could not be 
confirmed due to gaps within the sequences196. 
 
 PNG 413-415  
Contrary to chronic infection variants, TFs tended not to carry a PNG at position 413-415, 
suggesting that this site is selected against during transmission, or shortly thereafter8. The 
PNG at position 413-415 has also been associated with a conserved sequence motif, RIKQ 
(HXB2 position 419-422), a few residues upstream.  This conserved motif has been found to 
be involved with CCR5197 and antibody binding56. Since PNG413 is almost always found to be 
glycosylated when present198, it has been hypothesised that due to its close proximity to RIKQ, 
the glycosylation of the PNG physically prevents epitope recognition by host antibodies. This 
may provide a mechanism for escape from the host immune response, improving the chance 
of survival199. However, escape mutations have been shown to carry a fitness cost and 
changes in N-glycosylation could influence protein expression, processing and function150. 
Therefore, selection of variants lacking PNG415 during transmission could be beneficial for 
viral survival post-transmission as these variants could have higher replicative fitness. 
 
 Histidine at position 12 of the Env signal peptide 
Env-SP in retroviruses, particularly that of HIV-1200 has been shown to influence protein 
cleavage rate102, folding126,201, trafficking and processing47,92. Exchange of the endogenous 
signal peptide with heterologous ones from erythropoietin (EPO) or tissue plasminogen 
activator (t-PA)135, increased the expression levels and secretion202 as well as the 
incorporation of Env and the infectivity of the virions136. His12 in the signal peptide of subtype 
B Envs has been shown to increase expression of the Env, resulting in better incorporation 
and thus more infectious viral particles13. This suggests that the presence of His at position 12 
could influence the replicative fitness of the TF so that its presence is required for successful 
transmission. In 2018, another study showed that substituting His12 with Arg, Gln or Tyrosine 
(Tyr), reduced virion- and cell-associated Env levels as well as infectivity of infectious 
35 
 
molecular clones (IMCs) without influencing Env synthesis and cleavage203. This finding did 
not only support Asmal et al. (2011) but also showed that the presence of Gln at position 12 
was associated with enhanced sensitivity to monoclonal antibodies due to alterations in Env 
N-glycosylation. Therefore, changes in the signal peptide can influence Env N-glycosylation 
and antibody sensitivity. Unlike subtype B Envs, subtype C Envs do not carry a His at position 
12, suggesting that the replicative fitness of subtype C TF is not dependent on His at this 
position but that other amino acids could provide a similar advantage during HIV-1 
transmission.  
 
Current vaccine strategies require high levels of Env expression136 for purification that can 
induce long-lived neutralising antibody responses for a broad range of virus variants204. To 
achieve this, expression systems that can facilitate high-level expression without 
compromising the structure and function of the protein have to be utilised. If changes within 
the Env itself could be made to upregulate its expression whilst still maintaining correct 
folding and subsequent function in mammalian cells, this would facilitate the production of 
immunogenic Env. As subtype B TF Env naturally carries a Histidine at position 12 within the 
signal peptide and has been shown to increase Env expression, altering subtype C Env-SP 
sequence by mutational manipulations might increase expression without compromising Env 
structure and function. This approach would thus serve as an alternative to the use of 
heterologous signal peptides that are routinely used to increase Env expression for 
immunogen production.   
 
1.6 Concluding statements 
The enrichment of His12 and absence of PNG413 in Env of TFs would suggest that these sites 
are enhancing transmission by influencing viral replication. Env phenotypes that might 
enhance viral replication include increased levels of incorporation of Env trimers into viral 
particles and/or improved utilisation of CD4, CCR5, DC-SIGN and α4β7, or other unknown host 
factors that promote HIV infection. It follows that the more virus bound to host receptors the 
higher the viral replication. Both the signal peptide and N-glycosylation influences Env 
expression and processing, leading to increased incorporation of high levels of native trimers 
into infectious viral particles with or without changes in Env conformation that might enhance 
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interactions with CD4, CCR5 and/or DC-SIGN. We thus hypothesised that the two subtype B 
transmission motifs might function similarly to enhance transmission fitness by improving Env 
processing. A review of the literature highlighted the importance of the signal peptide and N-
glycans on viral fitness by altering expression, protein folding, function and immune escape.  
Characterisation of His12 suggested that replacing a His at position 12 with a neutral amino 
acid may slow down Env-SP cleavage, lower cell-surface expression and assist subtype B 
variants to evade neutralising antibodies during chronic stages of infection13. Following this 
suggestion, at transmission when there is no immune response, neutral amino acids at 
position 12 will not be beneficial. If neutral amino acids at position 12 are associated with a 
fitness cost, it might revert to consensus- a Histidine- in the absence of immune pressure. This 
suggests that His12 is not itself important for transmission but is required for optimal Env 
expression in the absence of an immune response. Alternatively, His12 may provide a direct 
advantage to TFs during transmission by enhancing infectivity. Interestingly, subtype C TFs 
tend to carry an uncharged Glutamine at position 12 in Env-SP, suggesting that: 1) Gln12 does 
not have a fitness cost and is thus transmitted, 2) His12 may not be a determinant in the 
transmission of subtype C variants or 3) TFs have evolved differently so that both Gln and His 
at position 12 of Env-SP have the same impact on transmission. Overall, studies aimed at 
elucidating the mechanisms by which these potential transmission motifs facilitate HIV 
transmission are crucial to our understanding of whether selection of these transmitted 
variants at the genital mucosa is subtype-specific and what this could mean for vaccine design. 
 
1.7 Study rationale and research objectives 
The transmission motif found at position 12 of the signal peptide not only influences subtype 
B Env expression and processing but also incorporation, contributing to the production of 
more infectious virus particles13. However, subtype C TF is not enriched for His at position 12, 
suggesting that this position is not required for subtype C transmission. Furthermore, the use 
of heterologous signal peptides to enhance Env production in vaccine production could alter 
the structure and immunogenicity of the immunogen. The absence of a PNG at position 413-
415 in subtype B Env has been found to provide a mechanism for immune escape during 
chronic infection by enabling resistance to potent and broadly neutralising host antibodies. 
Thus it has been suggested that this PNG is selected against in transmitted founder viruses 
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and may therefore also influence replication8. However, subtype C TFs carry a PNG at position 
413-415 suggesting that this might not be a transmission motif for subtype C variants. 
Therefore, this project aims to determine the importance of the Env signal peptide and the 
absence of PNG413 in subtype C transmission.   
 
1.7.1 Aim 
The overall aim of this project was to investigate the role of the transmission motifs identified 
in the Env of subtype B TF variants, i.e. His at position 12 of the signal peptide and the absence 
of a PNG at 413-415, in altering the expression, secretion, N-glycosylation, entry efficiency 
and replication of a subtype C TF variant.  
 
1.7.2 Objectives 
1. Generate subtype B TF Env signal peptide motif-carrying constructs using a subtype C 
variant. 
2. Compare expression, secretion and N-glycosylation patterns of Envs (wild-type, signal 
peptide mutants and T415I mutant). 
3. Generate pseudovirus from cloned Envs (wild-type, signal peptide mutants and T417I 
mutant) and compare entry efficiency using a reporter TZM-bl entry assay. 
4. Produce chimeric infectious molecular clones (IMCs) of wild-type, signal peptide 
mutants and T417I mutant using a yeast gap-repair assay. 
5. Replicate the IMCs in peripheral blood monocytic cells (PBMCs) and compare the 
replicative fitness of the IMCs to each other and compare to the entry efficiency of 
pseudovirus. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Envelope constructs 
The subtype C TF env clone, CAP210 E8 (donated by Gama Bandawe, IIDMM, UCT) was 
obtained from the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 002 
study cohort, isolated from a participant 5 weeks post infection. In order to characterise the 
env of the TF variant, single genome amplification (SGA) was performed. Viral RNA was 
extracted from the first plasma sample that tested either viral RNA or antibody positive. The 
next steps in SGA include cDNA preparation and limiting dilution in order to obtain a single 
template per PCR reaction followed by direct sequencing of the amplicon5,7,177. From the SGA-
derived env sequences, a consensus env sequence was generated which was most 
representative of the Env of the TF of that patient. The CAP210 E8 TF env SGA amplicon was 
then cloned into a mammalian expression vector, in this case the 5.1 kilobases (kb) long 
pcDNA3.1 V5-His Topo® (Life technologies™) for further genotypic and phenotypic 
characterisation. The PNG415 mutant (T417I) of this env clone was generated by Riley Traviss 
(IBMS, UCT) and included in this study. The signal peptide mutants, Q12H and Q12A, were 
generated by site-directed mutagenesis (Section 2.2.1). The soluble form of CAP210 E8, gp140 
was generated by Evelyn Ngwa (MCB, UCT) and was also mutated. 
 
2.2 Cloning and site-directed mutagenesis 
2.2.1 Site-directed mutagenesis 
A modified Quikchange® site-directed mutagenesis protocol (Stratagene) was used to 
generate signal peptide mutant CAP210 E8 clones. Complimentary primers carrying the 
desired mutations were designed and the NdeI restriction enzyme site was introduced 
through silent mutations using the online tool WATCUT (http://watcut.uwaterloo.ca). All 
primers were 40 nucleotides long with 15 bases on either side of the mutated nucleotides 
(Table 2.1) and were synthesised at the oligosynthesis laboratory by Pei-Yin Leibrich (MCB, 
UCT). All PCR reactions were performed in an XP Thermal cycler (Bioer technology). The DNA 
concentrations were determined using a NanoDrop® spectrophotometer (Thermo Scientific). 
PCR constituents are listed in Table 2.2. 
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Table 2.1: Site-directed mutagenesis primers 
*Nucleotide substitutions are bold faced and restriction enzyme recognition sequences are underlined. 
 
Table 2.2: Site-directed mutagenesis PCR mixture 
Reaction mix Concentration  
Buffer + MgCl2  1X  
dNTP mix  0.4 mM  
DMSO  5%  
Forward primer  0.5 μM  
Reverse primer  0.5 μM  
Template DNA  50 ng  
Phusion Hot Start Polymerase  1 U  
Total (made up with nuclease-free dH20)  50 μL  
 
Site-directed mutagenesis PCR was performed at an annealing temperature of 55 °C. The 
cycling conditions were as follows: 94 °C for 3 min followed by 25 cycles of 94 °C for 30 sec, 
55 °C for 30 sec, 72 °C for 12 min and a final elongation step at 72 °C for 20 min. To verify 
whether the PCR yielded the desired products, 8 μL of the product was separated on a 1% 
agarose gel. The template plasmid in the reaction mixture was digested with 20 U of DpnI 
(Thermo Scientific), a restriction enzyme that recognises methylated DNA so that only newly 
synthesised unmethylated plasmids were transformed into competent E. coli JM109 cells 
(Promega™).  
 
2.2.2 Bacterial cell culture, plasmid transformation and screening 
E. coli JM109 cells (Promega) used for production of plasmid DNA were grown in Luria broth 
(LB) growth media [1% tryptone, 0.5% yeast extract, 1% NaCl in distilled water and 100 μg/mL 
carbenicillin disodium salt (Sigma Aldrich®)] overnight at 30 °C with shaking. For plasmid 
Name Direction Sequence 5’3’ Restriction 
Enzyme 
CAP210_E8_Q12H_F Forward CAG AGG AAT TGG CAG CAC TGG GGC ATA TGG GGC ATC 
TTA G 
NdeI 
CAP210_E8_Q12H_R Reverse CTA AGA TGC CCC ATA TGC CCC AGT GCT GCC AAT TCC 
TCT G 
CAP210_E8_Q12A_F Forward CAG AGG AAT TGG CAG GCA TGG GGC ATA TGG GGC 
ATC TTA G 
CAP210_E8_Q12A_R Reverse CTA AGA TGC CCC ATA TGC CCC ATG CCT GCC AAT TCC 
TCT G 
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transformations, competent E. coli JM109 cells (Promega) stored at -80 °C were thawed and 
the desired amount of plasmid DNA was added to 50 μL of cells and incubated on ice for 20-
30 min. The cells were heat shocked for 45 seconds (sec) at 42 °C and immediately chilled at 
4 °C for 2 min. Cells were allowed to recover in 950 μL LB (without carbenicillin disodium salt) 
for 1 hour (hr) at 37 °C before centrifugation at 5000 revolutions per minute (rpm) for 5 min 
and 950 μL LB was removed. The cells were resuspended in the remaining LB, spread on Luria 
agar (LB, 1.5% w/v agar and 100 μg/mL carbenicillin disodium salt) plates and grown overnight 
at 30 °C205. Transformation efficiency controls were included at 10 pg, 100 pg and 1 ng of 
pcDNA3.1 (Invitrogen®). 
 
To screen for positive mutants, 5mL LB was inoculated from the LA plates containing 
transformants and grown O/N at 30 °C. Plasmid DNA from these O/N cultures was then 
extracted using the STET (8% sucrose, 5% Triton X-100, 50 mM Tris pH 8.0, 50 mM EDTA, 0.5 
mg/mL lysozyme) Boiling Preparation method206, a crude extraction method used initially to 
screen and identify colonies carrying the desired mutations with restriction enzyme digestion. 
After screening, glycerol stocks were made of potential positive mutants before colonies were 
cultured in 5 mL LB O/N for plasmid extraction by the Bioflux™ Plasmid DNA Extraction Kit 
(Bioer Technologies) according to the manufacturer’s instructions. Plasmid DNA was eluted 
with 50 μL of nuclease free water and sent for sequencing to confirm that the desired 
mutations were present. 200-300 ng of this DNA was digested (Section 2.2.3) with NdeI (Table 
2.1). 
 
2.2.3 Restriction enzyme digestion  
Restriction enzyme digestions were carried out in 20-50 μL reaction mixtures containing DNA 
(200-300 ng), enzyme buffer (1X) and 1 unit (U) of the appropriate restriction enzyme. NdeI 
and PacI were purchased from Thermo Scientific™ and digestions with these enzymes were 
performed at 37 °C for 1 hr. 
 
2.2.4 Agarose gel electrophoresis  
Agarose gel (0.8% or 1% w/v) were prepared by adding the appropriate amount of agarose 
(Whitehead Scientific™) to TBE buffer (2 mM EDTA, 89 mM Tris base and 89 mM boric acid) 
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boiled until complete dissolution followed by addition of ethidium bromide (0.3 μg/mL). DNA 
was mixed with loading buffer (5% glycerol and 0.001% bromophenol blue in distilled water) 
and separated by agarose gel electrophoresis in TBE buffer at 100 volts (V) until the desired 
bands could be visualised.  
 
2.2.5 Sequence analysis 
After screening colonies for SDM mutants using restriction enzyme digestion by NdeI, the 
plasmid DNA was extracted (Section 2.2.3) and sent to the Central Analytical DNA Sequencing 
Facility at the University of Stellenbosch. All primers used are listed in Table 2.3 below. Upon 
identification of potential mutants, primers Rev15 and EF175 which span the signal peptide 
region of the Env (HXB2 numbering) were used to confirm the presence of the mutations. 
Thereafter the remaining 6 primers which cover the entire env were used to check for any 
additional mutations. All primers used are listed in Table 2.3 below. 
 
Table 2.3: Primers used for sequencing of the full-length HIV-1 env gene after site-directed 
mutagenesis 
Primer name Direction Primer sequence Length 
(bp) 
HXB2 position 
(entire genome) 
Rev15 Reverse CTG CCA TTT AAC AGC AGT TGA GGT GA 26 6990←7012 
EF175 Reverse TTT AGC ATC TGA TGC ACA GAA TAG 24 6378←6398 
For14 Forward TTG CCA ATC AAG GAA GTA GCC TTG TGT 27 6559 
EF15 Reverse CTT GCT CTC CAC CTT CTT CTT C 22 8424←8442 
EF00 Forward GGG AAA GAG CAG AAG ACA GTG GCA ATG A 28 6204→6228 
EF55 Reverse GCC CCA GAC CGT GAG TTG CAA CAT ATG 27 7914←7937 
E200 Forward GGG ATA ACA TGA CCT GGA TGC AGT GGG 27 8095→8118 
EF260 Forward TTC AGC TAC CAC CGA TTG AGA GAC T 25 8523→8544  
 
2.3 Mammalian cell culture  
HEK 293T, the human embryonic kidney cell line and TZM-bl cells (obtained through the NIH 
AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. John C. Kappes, Dr. Xiaoyun Wu 
and Tranzyme Inc)207, are adherent cell lines that were maintained in growth medium made 
up of Dulbecco Modified Eagle high glucose medium (DMEM) (Sigma Aldrich®) supplemented 
with 10% fetal bovine serum (FBS) (Biocom Biotech®), 1 U/mL penicillin and 1 μg/mL 
streptomycin (Sigma Aldrich®). Cells were incubated and grown at 37 °C in a water-jacket 
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incubator (90% humidity and 5% CO2). Stocks of cells were stored in 10% Dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich®) in FBS (Biocom Biotech®) at -80 °C. All cells were tested for 
mycoplasma infection using the Fluorescent Hoechst DNA stain208 every month. 
 
2.4 Transient expression, secretion and N-glycosylation analysis of Env 
clones  
2.4.1 Plasmid preparation and transfection 
Plasmid DNA used for transfections was extracted from transformed E. coli cells that were 
initially inoculated into 5mL LB containing 100 ug/mL carbenicillin disodium salt and placed 
on a shaker at 30 oC for 10 hrs. These were either inoculated from picked colonies or glycerol 
stocks. The 5ml growth culture was transferred to 50 mL LB containing 100 ug/mL carbenicillin 
disodium salt and incubated at 30 oC with shaking for 16 hrs. Plasmids were purified using the 
PureYield™ Plasmid Midiprep System (Promega®) according to the manufacturer’s 
instructions. HEK 293T cell monolayers were lifted with 1% trypsin (Whitehead Scientific™), 
stained with trypan blue (Lonza®), counted using a haemocytometer. In order to determine 
the number of viable cells present, cells were resuspended 1 in 10 in trypan blue (Lonza®), a 
dye which may only be taken up by dead cells that do not possess an intact cell membrane. 
All cells which appeared blue were excluded from the cell count. Cells were seeded at a 
density of 4x105 cells/well in a 6 well plate (NEST®) in 2 mL of growth medium and incubated 
overnight at 37 °C in a water-jacket incubator (90% humidity and 5% CO2). When the cell 
monolayers were 50-60% confluent, they were co-transfected with 3.25 μg of either env 
clones or an empty vector control, pcDNA3.1 V5-His Topo® (Invitrogen®) and 0.5 μg of pGL4-
luc+ vector using Polyethylenimine [PEI (Sigma Aldrich®)]. In 400 μL of DMEM, 21 μL of PEI (1 
mg/mL) was mixed with 3.25 μg of DNA. The mixture was vortexed vigorously for 15 sec and 
incubated at room temperature for 10 min to allow for DNA: PEI-complex formation. Growth 
medium was removed from HEK 293T cells and fresh medium was added to the cells before 
the DNA: PEI-mix was added drop wise. After incubation for 6 hrs to allow cells to take up the 
DNA, the growth medium was replaced with fresh growth medium and the cells were 
incubated for 48-72 hrs for expression of the Env protein.  
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2.4.2 Cell lysis and measuring transfection efficiency 
Growth medium was removed from the HEK 293T cells. Cell associated Env (gp160, gp120 and 
gp140) was harvested by adding 300 μL of RIPA lysis buffer (10 mM Tris buffer pH 7.5, 2 mM 
Na2EDTA pH 8, 150 mM NaCl2, 1% Triton X-100 detergent and 10 mM phenylmethanesulfonyl 
fluoride (PMSF) [Sigma Aldrich®] per 50 mL buffer solution) to each well of the six-well culture 
plate. Lysis was carried out for 10 min at 4 °C or on ice and the cell debris was removed by 
centrifugation of the lysates at 14000 rpm for 2 min at 4 °C. In order to read luciferase 
luminescence due to transfection control pGL4-luc+ vector, 30 μL of the supernatants were 
added to an opaque 96 well plate (Porvair®) and 30 μL of BriteGlo® lysis buffer (Promega®) 
was added and incubated for 2 min at room temperature. Luciferase activity was measured 
using a luminometer (Glomax® 96 Modulus Microplate) and relative light units (RLU) was used 
as an indicator of luminescence. The supernatants were stored at -20 °C and used for protein 
concentration determination and Env expression experiments. For cells transfected with 
soluble gp140 env constructs, the growth medium from the HEK 293T cells was used 
immediately (Section 2.4.4) as it contained the released soluble protein.  
 
2.4.3 SDS-PAGE and Western blotting  
Total protein concentration of the cell lysates was determined using a Bradford assay (Bio-
Rad) according to the manufacturer’s instructions. A standard curve was constructed using 
bovine serum albumin (BSA) and used to determine the unknown protein concentration of 
cell lysates. To compare Env expression levels, duplicates of BSA standards (concentration 
range of 0-2000 µg/µL) were averaged and the protein concentration of Bradford assay 
(BioRad®) was calculated from a BSA standard concentration curve, to normalize the total 
protein concentrations in the relative samples (Microsoft Excel™ 2010) for western blot 
analysis. The desired amount of protein was mixed with loading buffer (1% SDS, 8% glycerol, 
1% β-mercaptoethanol, and 0.01% bromophenol blue) and denatured for 10 min at 90 °C. 
Proteins were separated by electrophoresis under denaturing conditions using 8% Bis-Tris 
polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membrane (Immuno-
Blot®, Bio-Rad) with transfer buffer (25 mM Tris, 192 mM glycine and 20% methanol) at 100 
V for 1 hr using a wet transfer system (Bio-Rad). For Env expression experiments, the house-
keeping protein β-actin, was used as a loading control. The membrane was cut into two 
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sections for detection of the higher molecular weight Envs (160 and 120 kDa) and the lower 
molecular weight β-actin (43 kDa). For Env processing experiments, the gp41 portion of the 
full-length Env was detected. The membranes were incubated overnight in blocking buffer 
(5% fat free skim milk and 0.5% Tween-20 in TBS [50 mM Tris, 150 mM NaCl, pH 7.5]) at 4 °C. 
The membranes were incubated with the appropriate concentration of primary antibodies 
(Table 2.3) made in blocking buffer for 1 hr at room temperature with shaking. The 
membranes were then washed four times with rinsing, in 15 min intervals, with 0.5% Tween-
20 in TBS and the appropriate secondary antibody (Horse-radish peroxidase conjugated Goat 
anti-sheep IgG or Goat anti-mouse IgG for gp120 and β-actin, respectively) (Table 2.4) made 
in blocking buffer was added and incubated for 1 hr at room temperature with shaking. The 
membrane was then washed four times, with 15 min intervals, with TBS-T and then with TBS 
only to remove residual 0.5% Tween. Enhanced chemiluminescence using the Lumino Glo® 
substrate kit (KPL) and autoradiography films (Santa Cruz Biotechnology®) were used for 
visualization. The density of each of the bands on the autoradiography film was determined 
using Image J™, which measures the intensity in pixels of each band and generates peaks. The 
area under each peak is determined automatically and the percentage relative to the total 
area is given. The percentage for the wild type (reported as a density) was then used to 
determine the relative densities of each of the samples. These relative density values were 
then divided by the densities obtained for the actin control, i.e. the adjusted density. These 
adjusted densities were then used for statistical analyses. 
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Table 2.4: Antibody specifications  
 
*The antibody was obtained through the NIH AIDS Reagent Program (ARP), Division of AIDS, NIAID, NIH: 
Antiserum to HIV-1 gp120 from Dr. Michael Phelan. 
 
2.4.4 Secretion, cleavage efficiency and N-glycosylation analysis of Env 
HEK 293T growth medium (1 mL) (Section 2.4.2) from transient expression of the soluble 
gp140 Env was centrifuged at 14 000 rpm for 2 min at 4 °C to remove residual cell debris then 
diluted with 1mL of MES binding buffer (20 mM morpholinoethanesulfonic acid, 130 mM 
NaCl, 10 mM CaCl2) at 4 °C. For each Env protein extract, 30 μL of N-Galanthus nivalis agarose 
beads (Vectorlabs®) was added and binding between the lectin agarose beads and Env was 
carried out overnight at 4 °C with gentle mixing on a rolling apparatus in 2 mL Eppendorf® 
tubes. The agarose beads were centrifuged at 14000 rpm for 3 min at 4 °C and the supernatant 
was removed. If the pelleted beads could not be observed after centrifugation, the samples 
were centrifuged once more as before. For endoglycosidase treatments, beads were washed 
twice with 1 mL phosphate buffered saline (PBS) (Sigma-Aldrich®) at 4 °C, supplemented with 
0.9 mM CaCl2 and 0.49 mM MgCl2 and then treated with endo-β-N-acetylglucosaminidase H 
(Endo H) (0.5 U) or peptide N-glycosidase F (PNGase-F) (0.5 U) according to the 
manufacturer’s instructions (New England Biolabs®) then analysed by SDS-PAGE and Western 
blotting. For secretion analyses, beads were washed four times with phosphate buffered 
saline (PBS) (Sigma Aldrich®) at 4°C and bound protein eluted with 40 μL 1 M Methyl α-D-
Mannose-Pyranoside (MMP) (Sigma Aldrich®). The total volume of eluted protein was then 
Name  Protein recognised  Dilution  Source  
Sheep anti-gp120  Polyclonal serum 
specific for HIV-1 
gp120 
1:2500  ARP* Catalogue 
number 288 
Mouse anti-actin  β-Actin  1:4000  Sigma-Aldrich®  
Sheep anti-HIV-1-p24 gag 
(D7320) 
HIV-1 p24 1:600 
 
Aalto Bio reagents 
Ltd. 
Alkaline Phosphatase-mouse 
anti-HIV-1 p24 
HIV-1 p24 
 
1:64000 
 
Aalto Bio reagents 
Ltd 
Horse-radish peroxidase-Goat  
anti-sheep IgG  
Secondary sheep 
antibodies  
1:4000  Santa Cruz 
Biotechnology®  
Horse-radish peroxidase-Goat  
anti-mouse IgG  
Secondary mouse 
antibodies  
1:4000  Santa Cruz 
Biotechnology®  
Horse-radish peroxidase-Goat 
anti-human IgG 
Secondary human 
antibodies 
1:4000 Santa Cruz 
Biotechnology®  
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halved for SDS-PAGE and Coomassie staining  or Western blotting in order to normalise total 
protein and compare levels of secretion, respectively209. Once the endoglycosidase treated 
Envs were visualized by autoradiography, the molecular weights of the bands were 
determined using their migration distances. A standard curve of log molecular weight vs. 
relative migration distance (Rf) was generated, based on the values obtained for the bands of 
the molecular weight ladder. The Rf was measured from the top of the gel to the centre of 
the bands. The molecular weight of glycosidase treated and untreated Env bands were then 
calculated. Differences in N-glycosylation were determined by comparing the molecular 
weight of the demannosylated Env and deglycosylated Env with the untreated samples in 
order to determine the degree of mannosylation210. To calculate cleavage efficiency of 
secreted gp140, the densities of cell associated-gp140, gp140 and gp120 in the culture 
medium after western blotting was used to determine the relative level of gp120 expressed 
as a percentage of total Env. 
 
2.5 Pseudovirus production and p24 assay  
2.5.1 Transfections  
To produce pseudoviruses, HEK293T cells were transfected as above (Section 2.4.1) with the 
following modifications: PEI (21 μg) was mixed with 2.5 μg of each env clone and 5 μg of the 
viral backbones pSG3Δenv or pNL4.3-R-E-luc+. After 48 hrs, growth medium containing the 
pseudoviruses was collected and clarified through a 0.22 μm pore size filter. The pseudovirus 
stocks were stored at -80 °C in growth medium supplemented with 20% FBS and an aliquot 
was inactivated with 1% Empigen® (Sigma-Aldrich®) in TBS to determine p24 concentration.  
 
2.5.2 p24 enzyme-linked immunosorbent assay (ELISA)  
In order to determine the concentration of pseudoviruses, a chemiluminescent p24 in-house 
ELISA (Aalto Bio reagents) and the TROPIX® detection system (CDP-Star®, Applied Biosystems) 
was used. High bind assay plates (Whitehead Scientific™) were coated with 100 μL of sheep 
anti-HIV-1 p24 gag antibody (Table 2.4) diluted to a final concentration of 2 μg/mL in coating 
buffer (100 mM NaHCO3 pH 8.5) and incubated overnight at room temperature. Unbound 
antibody was removed, and the wells were washed three times with 100μL TBS. Plates were 
blocked with 5% BSA (Biocom Biotech®) in TBS for 1-2 hrs at room temperature and thereafter 
47 
 
stored at -20 °C until needed. Serial dilutions of the inactivated pseudoviruses were made in 
1% Empigen®-TBS and 100 μL was added to the antibody coated plates that were washed four 
times to remove BSA. A purified p24 protein (0-32 ng/mL) (Aalto Bio reagents) was serially 
diluted in 1% Empigen®-TBS and used to construct a standard curve. After addition of samples 
and p24 standards in duplicate to the appropriate wells, the plates were incubated for 3 hrs, 
before unbound p24 was removed and the wells washed four times with 100 μL TBS. An 
alkaline phosphatase conjugated mouse anti-HIV-1 p24 antibody (Aalto Bio reagents) was 
diluted with TBS-0.1% Tween-20 (TBS-T) containing 20% sheep serum (Biocom Biotech) and 
2% BSA and 100 μL was added to the plates and incubated for 1 hr at room temperature. 
Unbound antibody was removed and washed with 100 μL TBS-T eight times and then twice 
with 100 μL 1X TROPIX® buffer (200 mM Tris, 10 mM MgCl2 pH 8.9). The detection reagent 
was diluted four times with TROPIX® buffer and 50 μL was added to the wells. Luminescence 
was read using a multi-well plate reader (Turner Biosystems® Modulus Microplate). Relative 
light units (RLU) of pseudovirion samples were converted to p24 concentration (ng/mL) using 
a standard curve and non-linear regression analysis using Microsoft Excel™ 2010.  
 
2.6 Entry efficiency assay  
To determine the entry efficiency of the pseudovirion stocks, a TZM-bl cell assay was used. 
The TZM-bl cell line is a genetically engineered HeLa cell clone that expresses CD4 and co-
receptors CCR5 and CXCR4. These cells contain a luciferase reporter gene under the control 
of an HIV-1 long terminal repeat which is induced upon infection with HIV-1 due to the 
presence of the Tat protein211,212. TZM-bl cell monolayers were lifted with 1% trypsin, stained 
for cell viability as described before (Section 2.4.1) and counted using a haemocytometer and 
104 cells in 200 μL growth medium were seeded per well in a 96 well plate (NEST®). The cells 
were incubated overnight at 37 °C in a water-jacket incubator (90% humidity and 5% CO2). On 
the day of infection, the cell monolayers were 50-60% confluent and 5-fold serial dilutions of 
the pseudoviruses was made in growth medium. All pseudovirus stocks were normalised to 
either 100 ng/mL or 250 ng/mL p24 prior to serial dilution. Half of the growth medium was 
removed from each well and replaced with 100μL of titrated pseudoviruses in triplicate. 
Pseudovirus single round infection was carried out for 48 hrs at 37 °C in the presence of 
pseudovirus. Growth medium (150 μL) with input pseudovirus was removed from the cells 
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and 50 μL of BriteGlo® lysis buffer (Promega®) was added. Cells were lysed for 2 min at room 
temperature, mixed gently and 100μL was transferred to an opaque 96 well plate (Porvair®). 
Luciferase activity was measured using a luminometer (Glomax® 96 Modulus Microplate) as 
a proxy for single round replication. RLU curves were plotted by subtracting background RLU 
obtained from cells to which no virus was added from each triplicate value. The standard 
deviation of the triplicate values was determined (Microsoft Excel™ 2010) and plotted 
showing the fold change in entry efficiencies normalised to the wildtype were plotted using 
GraphPad Prism™ 5.  
 
2.7 Production of chimeric Infectious Molecular Clones (IMCs) 
2.7.1 PCR amplification of the env gene 
In order to generate chimeric infectious molecular clones (IMCs), the env gene from the 
CAP210 E8 TF env constructs had to be PCR amplified. Primers were designed in order to 
anneal to regions which flank the env gene and are needed for homologous recombination 
with the subtype B proviral backbone, pCMV-PBS-LTR-NL4-3∆gp160/URA in yeast cells213,214. 
PCR constituents are listed in Table 2.5.  
 
Table 2.5: Conventional env primers for homologous recombination in yeast 
 
Table 2.6: env amplification PCR mixture 
Reaction mix Concentration  
Buffer  1X  
dNTP mix  0.2 mM  
MgCl2 or MgSO4 1.5 mM  
Forward primer  0.2 μM  
Reverse primer  0.2 μM  
Template DNA  1-50 ng  
DNA Polymerase   1-2 U  
Total (made up with nuclease-free dH20)  50 μL  
 
Name Direction Sequence 5’3’ 
Env_IF Forward AGA AAG AGC AGA AGA CAG TGG CAA TGA 
Env_IR Reverse TTT TGA CCA CTT GCC ACC CAT 
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Env PCR was performed at an annealing temperature of 55°C using either KAPA HiFi Taq DNA 
Polymerase kit (KAPA Biosystems®), Phusion Hotstart Polymerase (ThermoFischer®), Q5 High 
Fidelity Polymerase (New England BioLabs®) or Platinum Taq High Fidelity Polymerase 
(Invitrogen®). The cycling conditions were as follows: 94-98 °C for 2 min followed by 25 cycles 
of 94 °C for 30 sec, 55 °C for 30 sec, 68 °C or 72 °C for 90 sec and a final elongation step at 68 
°C or 72 °C for 4 min. To verify whether the PCR yielded the desired 3 kb product, 5 μL of the 
product was separated on a 0.8% agarose gel. Upon confirmation of successful PCR, the 
remainder of the PCR products were purified using the Wizard® SV Gel and PCR Clean-Up kit 
using the manufacturer’s instructions (Promega®).  
 
2.7.2 Yeast gap-repair assay 
The generation of chimeric IMCs carrying env clones using the yeast gap-repair system213 
involves the homologous recombination of the PCR amplified env and the linearised pCMV-
PBS-LTR-NL4-3∆gp160/URA backbone in yeast cells by transformation.  
 
For transformations, S. cerevisiae competent S288C cells prepared as previously described215 
stored at -80°C were thawed and 100 μL cells pelleted by centrifugation at 13 000 rpm for 30 
sec. The supernatant was discarded and the following reagents added in this order: env and 
linearised pCMV-PBS-LTR-NL4-3∆gp160/URA vector at 1 μg and 0.2 μg, respectively; 10 μL 
salmon sperm DNA (Invitrogen®); 240 μL 50% w/v polyethylene glycol (PEG); 36 μL 1M lithium 
acetate and distilled water to a total volume of 370 μL. Cells were incubated at 30 C for 30 
min followed by heat shock at 40 C for 15 min. Cells were then centrifuged at 13 000 rpm for 
30 sec and the supernatant discarded. Cell pellets were resuspended in 100 μL Tris-EDTA (TE) 
buffer (100 mM Tris, 10 mM EDTA at pH 8.0). Resuspended cells were spread on yeast amino 
acid dropout agar [2% peptone, 1% yeast extract, 2% w/v agar, 0.67% w/v complete 
supplement mixture minus leucine (CSM-leu), 2% dextrose, 0.1% w/v 5-fluoro-1,2,3,6-
tetrahydro-2,6-dioxo-4-pyrimidine carboxylic acid (FOA; Zymo Research Corporation™) in 
distilled water] and grown 2-3 days at 30 C. Transformation efficiency controls were 
included: 0.2 μg of undigested pCMV-PBS-LTR-NL4-3∆gp160/URA vector. Replica plates of all 
colonies were made for further screening and following positive identification of homologous 
recombination were cultured in 2 mL yeast amino acid dropout media [2% peptone, 1% yeast 
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extract, 0.67% w/v complete supplement mixture minus leucine (CSM-leu), 2% dextrose in 
distilled water] overnight at 30 C.   
 
2.7.3 Colony PCR  
To screen for positive colonies with env inserted in the correct orientation into the pCMV-
PBS-LTR-NL4-3∆gp160/URA backbone, colony PCR with the env specific forward and reverse 
primers, FW-Env-Y and RV-Env-Y were used. If the env amplicon was not inserted by 
homologous recombination, then a PCR product of approximately 1 kb would not be amplified 
using the Q5 High Fidelity Polymerase kit (Inqaba Biosystems®). Single colonies were picked 
using sterile tips and added to a reaction mixture whose contents are listed in Table 2.7.  
 
Table 2.7: Colony PCR env primers for screening yeast 
 
Table 2.8: Colony PCR mixture 
 
 
The cycling conditions were as follows: 98 °C for 2 min followed by 25 cycles of 98 °C for 15 
sec, 55 °C for 30 sec, 72 °C for 90 sec and a final annealing step at 72 °C for 2 min. The presence 
of the ~1 kb PCR product (10 μL) was confirmed using a 0.8% agarose gel. Once positive clones 
were identified, replica colonies were inoculated and cultured as described above (Section 
2.7.2). Plasmid DNA for transformation into commercial electro-competent E. coli cells (New 
England BioLabs®) was extracted from yeast cells using the Zymoprep™ Yeast Plasmid 
Miniprep Kit (Zymo Research Corporation®) according to the manufacturer’s instructions. IMC 
chimeras were confirmed by sequencing as before (Section 2.2.5).  
Name Direction Sequence 5’3’ 
FW-Env-Y Forward AAT GTC AGC ACA GTA CAA TGT ACA CAT GG 
RV-Env-Y Reverse GGA GCT GTT GAT TTA GGT ATC TTT C 
Reaction mix Concentration  
Buffer  1X  
dNTP mix  0.2 mM 
FW-Env-Y 0.2 μM  
RV-Env-Y 0.2 μM  
Q5 High Fidelity Polymerase   1 U  
Total (made up with nuclease-free dH20)  25 μL  
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2.7.4 Transformation of electro-competent E. coli cells 
Following the isolation of full length chimeric IMC DNA from yeast cells (Section 2.7.4), the 
DNA was then transformed into electro-competent E. coli cells (New England BioLabs®). Cells 
stored at -80°C were thawed on ice for 10 min and mixed gently by inversion. 25 μL of cells 
were transferred into pre-chilled microcentrifuge tubes and 1-2 μL of the desired DNA added 
to the cells. The cell/DNA mix was then transferred into pre-chilled 1 mm electroporation 
cuvettes (Biorad®) and electroporated using 2 kilo Volts (kV), 200 ohms (Ω) and 25 micro 
Farad (μF). 975 μL of pre-warmed SOC outgrowth medium (2% tryptone, 0.5% yeast extract, 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 in distilled water) was added 
immediately with gentle mixing. Cells were allowed to recover for 1 hr at 37 °C. 100 μL cells 
were spread on Luria agar (LB, 1.5% w/v agar and 100 μg/mL carbenicillin disodium salt) plates 
and grown overnight at 37 °C205. Transformation efficiency controls were included at 10 pg of 
pUC19 (Invitrogen®). Colonies were picked, cultured and plasmid DNA extracted as before 
(Section 2.2.2) for screening. 
 
2.7.5 Testing envelope functionality of chimeric IMCs 
The functionality of the chimeric IMC constructs (pCMV-PBS-LTR-NL4-3∆gp160/URA + env) 
(Section 2.7.4) was tested using the TZM-bl cell assay as outlined above (Section 2.6) with 
modifications. Firstly, the chimeric IMC constructs were transfected (Section 2.6.1) with the 
following modifications: HEK 293T cells were seeded at a density of 104 cells/well in a 96 well 
plate (NEST®) in 100 μL of growth medium and incubated overnight at 37 °C in a water-jacket 
incubator (90% humidity and 5% CO2). On the day of transfection the cell monolayers were 
50-80% confluent. For each well of a 96 well plate (NEST®), 50 μL of DMEM and 2 μL of PEI 
were mixed with 0.225 μg of chimeric IMC DNA and 0.225 μg of pCMV_NL4-3LTR-Gag4 helper 
plasmid DNA (donated by Dr Manish Sagar, Brigham and Women’s Hospital, Harvard Medical 
School, USA). HIV-1pNL4.3 full-length proviral backbone and pCMV-PBS-LTR-NL4-3∆gp160/URA 
were used as positive and negative controls, respectively. This was done in duplicate for each 
chimeric IMC construct and included a no virus control to measure background. The DNA-PEI 
mixture was incubated at room temperature for 15 min. All growth medium was removed 
from HEK 293T cells and replaced with 100 μL fresh growth medium. 50 μL of the DNA-PEI 
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mix was transferred to each well of the HEK 239T cells plate and incubated for 48 hrs. After 
24 hrs, TZM-bl cells were seeded at 104 cells per well in a 96 well plate (NEST®) in 200 μL 
growth medium and incubated overnight.  A volume of 100 μL growth medium was removed 
and HEK 293T cells supernatants (100 μL) were then transferred to the TZM-bl cells. Infection 
was carried out for 48 hrs at 37 °C and virus input was not washed out during this time. 
Luciferase activity was measured as outlined before (Section 2.6) and IMC constructs that 
gave luminescence 2.5-fold above background were selected for replication in donor PBMCs 
as previously suggested by Li et al. (2005).  
 
2.8 Replication assay 
2.8.1 Isolation of peripheral blood monocytic cells (PBMCs) 
Buffy packs were obtained from healthy donors who were negative for HIV-1, syphilis and 
hepatitis B and C from the Western Province Blood Transfusion Services. Ethics was approved 
by the Faculty of Health Sciences Human Research Ethics Committee at The University of Cape 
Town (approval number: 544/2017). Peripheral blood mononuclear cells (PBMCs) were 
isolated using Histopaque (Sigma-Aldrich®) gradient density centrifugation with Leucosep 
tubes (Greiner Bio-One®) according to the manufacturer’s instructions (Thorsby & Bratlie, 
1970). Fifteen mL Histopaque was loaded onto a Leucosep tube and centrifuged for 1 min at 
2500 rpm at room temperature. Whole blood was diluted 1 in 3 with 50% Roswell Park 
Memorial Institute medium (RPMI) 1640 (Lonza®), with no supplementation, and 50% 
phosphate buffered saline (PBS; Sigma-Aldrich®) and 30 mL of the diluted blood was added 
onto the 50 mL Leucosep tube with Histopaque followed by centrifugation at 2500 rpm for 
15 min at room temperature. After centrifugation, three layers were observed: PBMCs 
separate into a clean white buffy coat with red blood cells remaining in the Histopaque. The 
PBMCs were removed with a Pasteur pipette, and washed twice with PBS supplemented with 
1% (v/v) FBS (Biocom Biotech®). After each wash the samples were centrifuged for 5 min at 
1200 rpm. During the second wash, 10 μL of the PBMC sample in PBS was added to 90 μL 
trypan blue (Lonza®) and counted on a haemocytometer to determine cell number and 
viability. If PBMCs were still contaminated with red blood cells after the second wash an 
additional wash was performed to remove thrombocytes before counting. From one buffy-
coat ± 300-500 million (Ml) cells can be obtained. Isolated PBMCs were cultured in high 
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glucose (4.5 g/mL) RPMI 1640 (Lonza®) with 10% (v/v) FBS (Biocom Biotech®), 2 mM L-
glutamine (Sigma-Aldrich®), 25 mM HEPES (Lonza®) and 100 mg/mL penicillin and 100 mg/mL 
streptomycin (Sigma-Aldrich®) at 37 °C in a water-jacket incubator (90% humidity and 5% CO2) 
for 72 hrs. To make cell stocks, cells were stained for cell viability (Section 2.4.1) and counted 
as before and centrifuged at 1500 rpm for 8 min and 20-50 MI cells were resuspended in a 
final volume of 1 mL in 10% DMSO (Sigma-Aldrich®) in FBS (Biocom Biotech®) and incubated 
at -80 °C overnight and stored in liquid N2. 
 
2.8.2 Transfection to produce infectious virus  
To produce chimeric IMCs, HEK293T cells were transfected as above (Section 2.4.1) with the 
following modifications: PEI (6 μg) was mixed with 1 μg of each chimeric IMC backbone 
(pCMV-PBS-LTR-NL4-3∆gp160/URA + env) and 1 μg of the helper vector pCMV_NL4-3LTR-
Gag4. After 48hrs, growth medium containing the viruses was collected and clarified through 
a 0.22 μm pore size filter. Virus stocks were stored at -80 °C in 500 μL growth medium 
supplemented with 20% FBS and an aliquot was inactivated with 1% Empigen® (Sigma 
Aldrich®) in TBS to determine p24 concentration (Section 2.5.2) and tissue culture infectious 
dose (TCID50).  
 
2.8.3 Tissue Culture Infectious Dose (TCID50) for titration of infectious virus 
In order to determine the virus titres of the chimeric IMCs (Section 2.8.2), the TZM-bl assay 
was used as described Edmonds et al. (2010) with a few modifications216. TZM-bl cells were 
seeded as before (Section 2.6) and infected with 4-fold serial dilutions of virus stocks, 
including a DMEM (growth medium only) control. Each dilution was performed in quadruplet 
and luminescence read after 48 hrs as previously described (Section 2.6).  The titre of the virus 
stock was determined using the Reed-Muench method and expressed as log infectious units 
(IU)/mL212. TCID50 was used in order to calculate the multiplicity of infection (MOI), i.e. the 
number of infectious particles per cell infected.  
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2.8.4 Testing PBMC donor selection 
To troubleshoot for differences in infectivity based on PBMC donor variation, PBMCs from 
three different HIV-negative donors were isolated as before (Section 2.8.1) and some cells 
were activated, and the remaining cells cryopreserved in liquid N2. Proliferation was 
stimulated with 200 U/mL natural human Interleukin-2 (IL-2) (Gentaur®) and 0.5 μg/mL 
phytohemagglutinin-P lectin (PHA-P) (ThermoScientific™) for 72 hrs in high glucose (4.5 g/mL) 
RPMI 1640 (Lonza®) containing 10% (v/v) FBS (Biocom Biotech®), 2 mM L-glutamine (Sigma-
Aldrich®), 25 mM HEPES (Lonza®) and 100 mg/mL penicillin and 100 mg/mL streptomycin 
(Sigma-Aldrich®). Activated PBMCs were seeded at a density of 106 cells/well in a 96 well plate 
(NEST®) in 100 μL and 300 TCID50 units of replication competent HIV-1pNL4.3 diluted in RPMI 
(with no supplementation) to a total volume of 200 μL used to infect in triplicate. 50 μL culture 
supernatant was collected for p24 ELISA (Section 2.5.2) and 50 μL fresh RPMI (no 
supplementation) was added to the plate for further culturing.  Viral replication in the three 
donors was compared by plotting the p24 ng/mL over days post infection. Donors which 
showed the highest replication for all viruses tested were taken forward for viral expansion 
of chimeric IMCs and all subsequent replication experiments.  
 
2.8.5 Viral expansion in activated donor PBMCs 
In order to produce high virus titre, IMCs produced in HEK 293T cells were expanded in 
PBMCs. Activated PBMCs were stained for cell viability as described before (Section 2.4.1) and 
plated in 6 well plates at a concentration of 5 X 106 cells per 2 mL of Full RPMI medium 
supplemented with IL-2 only. Virus stocks were thawed and 500 µL was added to the cells. 
Spinoculation was performed by centrifugation at 1500 x g for 2 hrs at room temperature to 
enhance cell infection. The infected cells were then transferred to T25-tissue culture flasks 
(NEST®) in a total volume of 5 mL Full RPMI supplemented with IL-2 so that cells were at a 
final concentration of 106 cells per mL. Cells were then incubated at 37 °C in a water-jacket 
incubator (90% humidity and 5% CO2) for 14 days. Infected PBMCs were refreshed with 5 
million activated PBMCs in fresh Full RPMI supplemented with IL-2 on day 7 and 500 μL virus 
supernatant was collected on days 7 and 10 post infection. Virus supernatant was aliquoted 
in cryovials and stored at -80 °C. 
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2.8.6 Concentrating IMCs by ultra-centrifugation  
To concentrate chimeric IMCs expanded in PBMCs (Section 2.8.5), virus was layered onto a 
20% glycerol cushion in a total volume of 5 mL and ultra-centrifuged in the Optima L-80 XP® 
ultracentrifuge at 26000 rpm for 2 hrs at 4 °C using the SW 55Ti rotor (Beckman Coulter). The 
virus pallets were resuspended in 50 μL of PBS and stored at -80 °C until required. 
 
2.8.7 Infection of activated PBMCs for replication kinetics 
Stored stocks of PBMCs identified to best support replication (Section 2.8.4) were thawed in 
supplemented high glucose (4.5 g/mL) RPMI 1640 (Lonza®) containing 10% (v/v) FBS (Biocom 
Biotech®), 2 mM L-glutamine (Sigma-Aldrich®), 25 mM HEPES (Lonza®) and 100 mg/mL 
penicillin and 100 mg/mL streptomycin (Sigma-Aldrich®). PBMCs were activated and seeded 
as before (Section 2.8.4) and 100 TCID50 units of each chimeric virus diluted in RPMI (with no 
supplementation) to a total volume of 200 μL used to infect in triplicate. HIV-1pNL4.3 virus was 
used as a positive control and cells without infection was included as a negative control. To 
enhance cell infection, spinoculation by centrifugation at 1 500 x g for 2 hrs at room 
temperature was performed. Infected cells were then incubated at 37 °C in a water-jacket 
incubator (90% humidity and 5% CO2) as before (Section 2.8.4). 50 μL virus supernatant was 
collected on day 0, 7, 10 and 14 post infection and stored at -80 °C for p24 ELISA (Section 
2.5.2). 50 μL fresh RPMI (no supplementation) was added to the plate for further culturing. 
Replication kinetics was plotted as p24 ng/mL over days post infection, average of the slope 
of each curves was calculated and plotted as a bar graph using GraphPad Prism™ 5.  
 
2.9 Statistical analyses 
To determine the fold changes in the expression and secretion of the Env after the 
incorporation of the mutations (Section 2.2.1) compared to the wild type, a one-way ANOVA 
with Tukey post-tests was performed using the GraphPad Prism™ 5. Histograms of the mean 
with standard error bars from the three biological repeats were generated. This statistical test 
was also used to compare the level of demannosylation after endoglycosidase treatment as 
well as entry efficiencies of pseudoviruses and chimeric IMCs. For the replication assay, the 
mean slopes of the curves of p24 concentration over time were calculated and plotted as a 
bar graph with error bars indicating the standard deviation of the mean slopes for the two 
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donors. GraphPad Prism™ 5 was used to perform a two-way ANOVA with Tukey post-test. 
Statistical significance was indicated as *, ** and *** for p-values less than 0.05, 0.01 and 
0.001. 
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CHAPTER 3: IMPACT OF SUBTYPE B TRANSMISSION MOTIFS 
ON SUBTYPE C ENVELOPE FUNCTION 
 
3.1 Introduction 
Seventy percent  of HIV-1 infections worldwide are due to heterosexual transmission  with 
the remainder owing to homosexual contact, maternal-infant infection, and injection drug 
use217. According to the 2017 UNAIDS Data Book, new infections among young women in 
2016 were 44% higher than they were among men in the same age group3, thus indicating 
that females at higher risk of infection than men218. With the female genital mucosa the 
primary site of HIV-1 transmission14, studies have focussed on how mucosal surfaces function 
as a barrier to the incoming virus. The low transmission rate per heterosexual coital act 
suggests that the genital mucosa is a formidable barrier219. Furthermore, the frequency of 
multiple variant infections were found to increase dramatically in the presence of chronic 
ulcerative disease or inflammatory genital infection in the recipient, suggesting that 
disruption of the barrier might abrogate mucosal protection179. Sexually transmitted 
infections (STIs) that cause inflammation have also been associated with increased 
susceptibility to HIV infection220 particularly in young women221,222. Elevated genital 
concentrations of chemokines and inflammatory cytokines have been suggested to contribute 
to the high risk of HIV acquisition in African women223. 
 
There has been a suggestion that the barrier function of the mucosa results in a genetic 
bottleneck during HIV transmission. The single variant, termed the transmitted founder (TF), 
is able to overcome the  mucosal barrier and establish infection due to a viral phenotype that 
provides an advantage during transmission15,177,178. TFs lack diversity within the env gene178 
and are R5-tropic, supporting the hypothesis that the viral Envelope (Env) may be  responsible 
for the selection of specific variants in the female genital tract (FGT)14,179,182. Currently 
prophylactic HIV-1 vaccine trials target either: a)  Env224 which is found on the surface of the 
virus and is responsible for binding to receptors on the surface of target cells and mediating 
the first step in viral replication15,177,178, or b) Gag, the capsid protein which encloses the viral 
RNA225. It has been hypothesised that TFs carry motifs within Env that facilitate 
58 
 
transmission226 and previous studies have identified phenotypic and genotypic characteristics 
of TFs that may play a role in their selection at the mucosal barrier74,227–230. 
 
Up to now, most research has focussed on HIV-1 subtype B which predominates in developed 
countries while subtype C contributes to 50% of infections globally2,231 and is the dominant 
subtype in Southern Africa17,232. The identification of common phenotypic traits essential for 
HIV-1 transmission may help in the development of a universal preventative vaccine by 
targeting these motifs across subtypes. However, thus far, Env phenotypes have differed 
across subtypes except that all TFs utilise CCR5 co-receptor for viral entry7 and are T-tropic227. 
Analysis of TF env sequences have revealed  that subtype A and C TF Envs have shorter 
variable loop lengths and thus less potential N-glycosylation sites (PNGS)15,65 whilst utilising 
CCR5 co-receptor only227. However, this trend for fewer PNG sites has not been consistent 
across all studies186 and not always observed for subtype B analyses8,185,190. Subtype B TF Envs 
were found to be enriched for a Histidine at position 12 of the signal peptide (His12)8. This 
polymorphism was found to increase Env expression leading to more infectious virus13. 
Gnanakaran et al. (2011) also showed that TF Envs lacked a PNG at position 413-415 whereas 
variants from chronic infection tended to carry a PNG at this site. Although the PNG at 413-
415 was proximal to receptor binding domains and could play a potential role in immune 
escape8 the motif was not characterised.  
 
The characterisation of TF Envs is important as the identification of potential transmission 
motifs can provide targets for the development of preventative vaccines. The two robust 
transmission motifs previously identified in TF env sequences of subtype B8, may provide 
insight into conserved motifs that are important in the transmission of all other subtypes. 
Therefore, the overall aim of this study was to investigate whether a subtype C TF variant, 
CAP210 E8, was phenotypically advantaged by His12 and PNG413 transmission motifs. Unlike 
subtype B env, subtype C TFs carried a Glutamine at position 12 (Gln12) within the signal 
peptide (Env-SP) and the PNG at position 413 was present. Thus, in this study CAP210 E8 was 
mutated to carry His12 and PNG413 was deleted and the mutants were characterised 
phenotypically to determine their potential influence on Env expression, secretion, N-
glycosylation and HIV-1 infectivity. 
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3.2 Results 
3.2.1 Site-directed mutagenesis of the TF env signal peptide 
In order to investigate whether the robust transmission motifs identified in subtype B TFs8 
influenced phenotypic properties of a subtype C TF variant lacking these motifs, these 
signatures were introduced by site-directed mutagenesis (SDM). The subtype C TF env clone, 
CAP210 E8 carried a Gln12 in its Env-SP that was mutated to either a His12 or an Ala12 residue 
(Figure 3.1). The Gln was mutated to an Ala to confirm that the His residue itself was 
important for Env function and not merely a change in amino acid identity. The PNG413 
recognition site was deleted by replacing a Threonine (Thr) at position 415 with an Isoleucine 
(Ile). The Ile residue was selected as it was the most common amino acid at that position of 
subtype C Envs of variants from chronic infection. These mutations were introduced in both 
the full-length (gp160) and soluble (gp140) forms of this env clone (Riley Traviss, IBMS, UCT) 
(Figure 3.1). The soluble env clone (generated by Evelyn Ngwa, MCB, UCT) has a stop codon 
introduced at position 686 (HXB2 numbering) upstream of the gp41 membrane spanning 
domain so that only 20kDa of gp41 is included after translation233,234. Although gp120 
monomers are typically used in studies where secreted Env is required, gp140 derivatives 
were used as it has been shown to readily form native Env trimers146,235–237.       
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 Confirmation of successful site-directed mutagenesis PCR 
The primers used for SDM PCR were designed to introduce a silent mutation 6 base pairs (bp) 
downstream of position 12 to include an additional NdeI restriction enzyme recognition site 
to screen for mutants. 
 
SDM of gp160 and gp140 was successful as a PCR product of approximately 8.1 kilobases (kb) 
was observed, corresponding to the size of the CAP210 E8 TF env clone (data not shown). The 
transformation of the DpnI-digested PCR products yielded ampicillin resistant colonies, and 
these were screened using restriction enzyme digestion by NdeI. A restriction map, indicating 
the position of the NdeI recognition sites and expected DNA fragments is shown in Figure 
3.2A.  
 
 
 
Figure 3.1: Graphical representation of the site-directed mutagenesis of the CAP210 E8 TF env clone. Soluble 
(gp140) and full-length (gp160) forms of the Env were mutated in their signal peptides and at a potential N-
glycosylation site (PNGS), indicated in green, generating six different constructs. Position 12 of the signal peptide 
is indicated by an arrow with mutations at this position from Glutamine (Q) to Histidine (H) or Alanine (A) in the 
respective env constructs. The Threonine (T) at position 415 of the PNG was mutated to an Isoleucine (also 
indicated in green). The stop codon present in the soluble Env is indicated by a red asterisk. 
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The expected banding pattern of wildtype (WT) CAP210 E8 full-length and soluble clones 
digested with NdeI included DNA fragments with molecular weights of 5518 bp and 2594 bp. 
The presence of the silent mutation that introduced an additional NdeI site digested the 2594 
bp band into 1654 bp and 940 bp DNA fragments. This 940 bp band was used to distinguish 
WT constructs from Env-SP mutants. After digestion with NdeI, the banding pattern of the 
plasmid extracted from these ampicillin resistant colonies had DNA fragments of molecular 
weights corresponding to 5518 bp, 1654 bp and 940 bp indicating that all four clones tested 
had been successfully mutated by SDM. Furthermore, when the clones were sequenced the 
introduction of the relevant base changes was confirmed (Figure 3.3) and no additional PCR-
derived mutations were identified in full-length env (data not shown). 
 
 
 
 
 
Figure 3.2:  Restriction enzyme digestion to screen for successful site-directed mutagenesis of the CAP210 E8 
TF env constructs. (A) A restriction enzyme map of CAP210 E8 env cloned into the pCDNA3.1 vector indicating 
the NdeI restriction enzyme sites with the site introduced via site directed mutagenesis indicated in purple by 
an asterisk. The signal peptide is indicated in green and the flanking regions of the env insert (in blue) are 
indicated in red. The sizes of the DNA fragments generated by NdeI digestion are shown. (B) Wild type (WT) and 
mutant (Q12H and Q12A) CAP210 E8 plasmid DNA was extracted from ampicillin resistant colonies after 
transformation and digested with NdeI before DNA fragments were separated on a 1% agarose gel. Gel 
electrophoresis of undigested (UD) and digested (D) WT and mutated clones are indicated. 
A B 
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3.2.2 Charge distribution of signal peptides 
The number of positively charged residues present in the N-terminal portion of Env-SP has 
previously been identified as determinants of the level of expression and secretion of Env107. 
Figure 3.4 shows the overall charge distribution (at physiological pH) within the first 14 amino 
acids of the CAP210 E8 TF env constructs versus a highly expressed subtype B TF env, AA0113  
carrying the transmission motif in the signal peptide. WT and signal peptide mutant Q12A 
appeared to have the same overall charge of +2 whilst Q12H had an overall charge of +3 due 
to the Gln to His substitution. The subtype B env however had the most positively charged N-
terminal region with a net charge of +4.  
 
 
 
 
3.2.3 Envelope expression  
Signal peptide cleavage is intrinsically linked with Env translation, folding and processing 
ultimately influencing expression levels238. Due to the association between signal peptide 
Figure 3.3: Confirmation of mutations at position 12 of Env-SP. WT CAP210 E8 TF env sequence was aligned to 
the four constructs generated by site-directed mutagenesis. Dots in the alignment indicate identical nucleotides 
to the CAP210 E8 WT sequence. The Glutamine to Histidine or Alanine mutation is shown as CAA to CAC or GCA, 
respectively.  Nucleotide changes to introduce these mutations and the additional NdeI restriction enzyme site 
(underlined in red) in CAP210 E8 SDM constructs are shown. Only the relevant region of env is shown although 
the entire env was sequenced. 
Figure 3.4: Schematic diagram of the charge distribution of the N-terminal region. The signal sequences of the 
CAP210 E8 TF env constructs (WT and signal peptide mutants, Q12H and Q12A) were aligned to that of a subtype 
B TF env12 to compare differences in overall charge. Plus (+) and minus (-) signs denote positively and negatively 
charged residues at physiological pH, respectively. 
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cleavage and protein expression levels HEK 293T cells were transiently transfected to express 
WT and mutant gp160 and gp140 and cells were lysed for Western blotting. As transfection 
efficiency could influence apparent expression levels, the firefly luciferase expression 
plasmid, pGL4-luc, was co-transfected (Figure 3.5). A representative graph of one 
independent experiment is shown to indicate the lack of variation in transfection efficiency 
between WT and mutants. This suggested that any variation in levels of cell-associated gp160, 
gp140 and gp120 detected by SDS-PAGE and Western blotting would not be due to 
transfection efficiency (Figure 3.6).  
 
 
 
 
The soluble recombinant gp120 used as a positive control migrated to approximately 129kDa 
which is 9 kDa greater than what was expected and gp160 and gp140 migrated at 164kDa and 
145kDa, respectively (Figure 3.6). The observed molecular weights of gp160 and gp140 were 
very similar to the expected sizes (160kDa and 140kDa, respectively) and the slight difference 
could be due to variation in N-linked glycosylation146,239. All gp160 and gp140 constructs 
expressed Env as a single dense band. As Western blotting was able to resolve bands 
representing gp160 and gp140 of 164kDa and 145kDa, respectively, it was unclear why gp120 
bands were not detected. It is possible that precursor Env, in this case uncleaved gp160 and 
Figure 3.5: Transfection efficiency of wild type and mutated env constructs. HEK 293T cells were transfected 
with env and pGL4-luc plasmid DNA (3.25 μg and 0.5 μg, respectively). Cell lysates were used to measure 
luminescence and luciferase readings were expressed as relative light units (RLU) in duplicate. Bar graph showing 
the average RLUs was plotted using GraphPad Prism® with error bars indicating standard deviation. 
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gp140, was more abundant relative to gp120 and thus easier to detect at this protein 
concentration. It has been reported that only a small fraction of gp160 is cleaved into gp120 
and this is dependent on cell type102. Asmal et al. (2011) used Jurkat cells to compare Env 
expression levels making it difficult to make a direct comparison between the two sets of 
data. However, gp120 was not detected for some clones analysed by Asmal et al. (2011) and 
there seemed to be an association between increased expression of gp160 and detection of 
gp12013. It was thus possible that by increasing the concentration of total protein per sample 
analysed by SDS PAGE might have improved detection of gp120, however even after loading 
150 µg of total protein, a single band representative of gp160 was observed (data not shown). 
However, we could not compare protein concentrations as these were not indicated by Asmal 
and colleagues. 
 
Furthermore, the bands corresponding to gp160 and gp140 lacked the smear expected of 
heavily glycosylated proteins235 and instead appeared as clear, sharp bands. Land et al. (2003) 
showed that most gp160 was found in the ER due to slow folding and delayed removal of Env-
SP126 thus most cell-associated Env would be carrying homogeneous high mannose N-glycans 
(Glc3Man9GlcNac2). Therefore, the sharpness of the bands corresponding to gp160 and gp140 
(Figure 3.5) could be due to homogeneous N-glycosylation.  
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Densitometry analyses normalised Env band intensities to the loading control, beta-actin 
(gp160/actin; gp140/actin) as well as transfection efficiency (Figure 3.5). Normalised densities 
of the mutants (Q12H, Q12A and T415I) were plotted as fold change in expression compared 
to WT (Figure 3.7). Signal peptide mutants, Q12H and Q12A, showed no significant difference 
in gp160 and gp140 expression compared to WT. Thus, unlike subtype B Env-SP, the His12 
within the signal peptide did not influence gp160 nor gp140 expression13,203. However, as 
Western blotting might not be sensitive enough to detect slight changes in expression, flow 
cytometry might have improved detection limits. 
 
In contrast, the expression of the T417I gp160 mutant was significantly 3.5-fold higher than 
WT (p=0.0034). The apparent lack of increased expression of the T415I gp140 mutant was 
likely due to the absence of a TM domain anchoring the mutant Env within the plasma 
membrane. Levels of cell-associated gp140 would not increase despite increased expression 
levels because, as soon as gp140 was processed and transported to the plasma membrane, it 
Figure 3.6: Expression of wild type and mutated env constructs. HEK 293T cells were transfected with env and 
pGL4-luc plasmid DNA (3.25 μg and 0.5 μg, respectively) and 100 μg of total protein was analysed by SDS-PAGE 
and Western blotting. Anti-gp120 and anti-actin antibodies were used to detect gp120 and gp160 and the 
loading control protein β-actin, respectively. The wild type (WT) and mutated (Q12H, Q12A and T415I) full-length 
and soluble Envs are indicated. Expected positions of the bands representing gp160, gp140 and beta-actin, 
indicated with an arrow, were based on the standard curve of the molecular weight marker. The plus sign (+) 
represents 30 ng of recombinant purified HIV-1 gp120 (IIB-CHO from the AIDS reagent programme) and the 
minus sign (-) represents cells transfected with an empty vector (pcDNA3.1 V5-His Topo® [Life technologies™]), 
used as a positive and negative control, respectively. The PageRuler Prestained Protein Ladder (Thermo 
Scientific) molecular weight ladder is indicated in kilo-Daltons (kDa). A representative of three independent 
experiments is shown. 
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was released into the medium. Therefore, if there was an increase in gp140 expression, then 
there should also be an increase in secreted gp140.  
 
 
 
 
3.2.4 Envelope secretion  
As the His12 enhanced secretion of subtype B TF Env13, and gp140 T415I cell-associated levels 
were not increased relative to WT despite increased gp160 expression, we wanted to 
determine whether CAP210 E8 mutants were secreted differently. To compare the secretion 
of gp140 carrying the subtype B transmission motifs to WT, the soluble env constructs were 
transfected into HEK 293T cells, the culture medium was collected and secreted Env was 
bound to N-Galanthus nivalis lectin-conjugated agarose beads in a pull-down assay (Section 
2.4.4) to concentrate the glycoproteins. It was highly likely that the amount of Env bound to 
the agarose beads varied between samples, making it difficult to compare mutants to WT. 
Therefore, we normalised Env to the total amount of glycoproteins bound to the N-Galanthus 
nivalis lectin beads using Coomassie staining209. One half of the total volume protein eluted 
from the N-Galanthus nivalis lectin-conjugated agarose beads was used for detection of 
Figure 3.7: Fold changes in expression of WT and mutated Env constructs. Densitometry analysis of three 
independent Western blots comparing gp160 and gp140 mutants to wild type (WT) were used to determine the 
fold-change in expression relative to WT. Fold-changes in expression of the WT full-length (gp160) and soluble 
Env (gp140) versus those containing the Q12H, Q12A or T417I mutations are indicated by each bar. An asterisk 
indicates statistical significance (** <0.01). Error bars indicate standard deviation and data was compared using 
GraphPad Prism™ 5 with a one-way ANOVA with the Tukey’s post-test. 
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gp120 via Western blotting (Figure 3.8A) and the other for quantification of total glycoprotein 
loaded on SDS-PAGE via Coomassie blue stain (Figure 3.8B).  
 
              
 
 
Gp140 may be secreted in two forms: uncleaved gp140 and gp120. As expected, two bands 
were observed for all soluble Env pull-down samples and had an apparent molecular weight 
of 145kDa and 125kDa, respectively (Figure 3.8A). Gp140 carrying the signal peptide 
mutations (Q12H or Q12A) showed no significant difference in the amount of total gp140 and 
gp120 secreted compared to WT (p > 0.05) (Figure 3.9), once again, contrary to the findings 
of Asmal et al. (2011). However, less Q12A gp120 was detected in the culture medium, 
suggesting that gp140 Q12A was not cleaved as efficienctly. On the other hand, the T415I 
gp140 and gp120  mutants were secreted 3-fold and 4-fold higher than WT, respectively (p < 
0.05), very similar to the fold change in gp160 expression. This strongly suggested that T415I 
Figure 3.8: Secretion of wild type and mutated gp140. HEK 293T cells were transfected with 3.25 μg soluble env 
(gp140) plasmid DNA and Env secreted into the culture medium partially purified using N-Galanthus nivalis lectin 
agarose beads (Vectorlabs®). Bound protein was eluted and half run on SDS-PAGE and analysed by Western 
blotting (A) and the other half separated by SDS-PAGE and stained with Coomassie (B). Anti-gp120 antibody was 
used to detect gp120 and gp140 and the Coomassie stain was used to control for loading. The WT (WT) and 
mutated (Q12H, Q12A and T415I) soluble Envs are shown and densitometry analysis was used to calculate the 
amount of total gp120 gp14 relative to the total protein per lane of the Coomassie stained SDS PAGE. Expected 
positions of the bands representing gp140 and gp120, indicated with an arrow, were based on the standard 
curve of the molecular weight marker. The plus sign (+) represents 30 ng of recombinant purified HIV-1 gp120 
(IIB-CHO from the AIDS reagent programme) and the minus sign (-) represents cells transfected with an empty 
vector (pcDNA3.1 V5-His Topo® [Invitrogen®]), used as a positive and negative control, respectively. The 
PageRuler Prestained Protein Ladder (Thermo Scientific) molecular weight ladder is indicated in kilo-Daltons 
(kDa). A representative of three independent experiments is shown. 
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gp140 was expressed to higher levels compared to WT, similar to gp160, which resulted in 
increased levels of secretion into the culture medium (Figure 3.9). 
 
 
 
 
Gp160 and gp140 T415I, had significantly enhanced levels of both expression and secretion 
compared to wild type. The high secreted levels indicated rapid release of gp140 into the 
culture medium thus preventing cell-associated gp140 levels from increasing. Therefore, 
increased expression of Env did not result in greater accumulation of unprocessed precursor 
in the ER, but instead, led to an increased proportion of Env trafficked to the plasma 
membrane.  
 
3.2.5 Envelope cleavage  
As viral infectivity depends on the incorporation of functional trimers92, gp160 cleavage into 
gp120 could be a very important determinant of pseudovirus fitness. His12 and PNG413 might 
influence gp160 cleavage so that fewer trimers are produced. However, cell-associated gp120 
Figure 3.9: Secretion of WT and mutated gp140 and gp120. The level of wild type and mutated gp140 secreted 
into the culture medium was determined by normalising the band intensities of uncleaved gp140 and gp120 by 
the total band intensity of the corresponding lane of the Coomassie stained gel. Levels of secretion are shown 
as mean fold changes relative to wild type with error bars representing standard deviation. Statistical analysis 
was carried out using GraphPad Prism™ 5 one-way ANOVA with the Tukey’s post-test. An asterisk indicates 
statistical significance (* < 0.05). This histogram represents the mean fold changes in Env expression of three 
independent experiments. 
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was not detected by Western blot and thus the cleavage efficiency of gp160 into gp120 could 
not be calculated as previously outlined240. Despite the absence of cell-associated gp120 
(Figure 3.6), gp120 was detected in the culture medium for gp140 WT and all mutants (Figure 
3.8A). This suggested that after gp140 cleavage, gp120 monomers or trimers were rapidly 
secreted into the culture medium leaving undetectable levels in the cell lysates. 
 
When gp140 was expressed by HEK 293T cells, uncleaved gp140 was detected in the culture 
medium indicating that a subset of protein was not cleaved into gp120 in transit to the plasma 
membrane (Figure 3.8A). The efficiency at which gp140 was cleaved may be influenced by the 
levels of Env expression and the abundance of the protein inside the ER84,107,124. However, a 
fraction of gp140 was converted to gp120 (Figure 3.10) and we hypothesised that the relative 
level of gp120 as a percentage of total Env, i.e. cell associated-gp140 and gp140 + gp120 in 
the culture medium would allow comparison of cleavage efficiency between gp140 mutants 
and WT240.  
 
 
 
 
Contrary to Q12H, the Q12A signal peptide gp140 mutant was cleaved approximately 2.3-fold 
less efficiently than WT. This suggested that when Alanine was at position 12, gp160 cleavage 
Figure 3.10: Cleavage of WT and mutated gp140 into gp120. To determine the efficiency at which gp140 was 
cleaved into gp120, the band intensity of gp120 was divided by the sum of the band intensities of gp120 and 
gp140 i.e. total Env expressed. Mean percentages of gp120 levels of three independent experiments were 
compared using GraphPad Prism™ 5 one-way ANOVA with the Tukey’s post-test. Wild type (WT), Q12H, Q12A 
and T415I Envs are indicated by patterned bars. Error bars represent standard deviation. An asterisk indicates 
statistical significance (*** < 0.001). 
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was reduced without any concomitant change in expression whereas the presence of a 
Histidine had no effect. Q12A gp120 levels in the culture medium were lower than WT 
possibly due to decreased cleavage efficiency.  However, as our method of determining 
cleavage was dependent on gp120 secretion, it is not possible to distinguish whether 1) more 
gp140 was cleaved and thus more gp120 secreted or 2) gp140 cleavage remained the same 
as WT but more gp120 was trafficked to the cell surface and directly released into the culture 
medium. Furthermore, as the relationship between an Alanine at position 12 and gp120 
secretion levels and gp140 cleavage did not reach significance, the apparent association might 
be due to experimental error and needs to be confirmed with cell-associated gp120 
expression studies. On the other hand, the gp140 T415I mutant was cleaved 1.5-fold 
significantly more efficiently than WT (p = 0.0005) (Figure 3.10). The significantly increased 
T415I gp160 expression (3-fold), increased gp140 and gp120 secretion (3-fold and 4-fold, 
respectively) and gp140 cleavage (1.5-fold) suggests that the loss of a PNG and/or Thr415 
could enhance the production of functional trimers, increased Env incorporation and 
improved viral infectivity.  
 
3.2.6 Envelope N-glycosylation  
Previous literature suggested that the loss of, or change, in a single PNG can lead to changes 
in the N-glycosylation profile of Env241. Changes in the distribution of N-glycans found on the 
fully processed Env have also been found to influence function by affecting binding to target 
cells and thus infectivity150,157,172,241–245. It has also been reported that an increase in Env 
expression can change the N-glycosylation profile of the protein such that predominantly high 
mannose N-glycans are added137.  Upadhyay et al. (2018), also found that mutation of His12 
altered the N-glycosylation profile. More recently, it was also shown that uncleaved gp140 
trimers enter an “aberrant pathways” where they are hyperglycosylated235. 
 
Cell-associated and secreted gp140 had the same molecular weight (Figure 3.6 vs Figure 3.8A), 
suggesting that most secreted gp140 resembled unprocessed ER-associated Env. Therefore, 
to determine whether over-expression, cleavage and secretion of the T415I mutant resulted 
in gp140 carrying mainly high mannose, gp140 was treated with endoglycosidases after 
expression in HEK 293T cells246. Digestion of Env with Endo-β-N-acetylglucosaminidase H 
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(Endo H) and Peptide N-glycosidase F (PNGase F) (New England Biolabs®), removes high 
mannose and all N-glycans, respectively. The shifts in molecular weights of the secreted Env 
before and after treatment with these endoglycosidases were measured (Table 3.1) in order 
to determine the percentage of mannosylation (Figure 3.12). Previously, soluble gp120 
constructs were utilised to characterise N-glycan structures on monomers50,247, however 
more recently gp140 have been used to analyse N-glycosylation within the context of native 
trimeric Env235. 
 
 
 
 
After PNGase F treatment of gp140 WT, 63kDa and 79kDa bands were observed that 
represented deglycosylated gp120 and gp140, respectively242,246 (indicated by green and red 
arrows in Figure 3.10). These molecular weights are similar to those predicted for wild type 
CAP210 E8 gp120 (59kDa) and gp140 (77kDa) (Table 3.1), confirming the accuracy of the 
methodology. The molecular weight of total N-glycans, i.e. that contributed by high mannose 
and complex sugars was determined by measuring the difference in the apparent molecular 
Figure 3.11: Digestion by endoglycosidases to determine the mannosylation of CAP210 E8 gp140 and gp120. 
Env was expressed in HEK 293T cells and soluble Env [Wild type (WT) gp140, Q12H gp140, Q12A gp140 and T415I 
gp140] was partially purified from the culture medium using N-Galanthus nivalis lectin agarose beads 
(Vectorlabs®) prior to digestion with Endo H (E), PNGase F (P) or left untreated (U) and analysed by SDS-PAGE 
and Western blotting. Red and green arrows indicate the position of deglycosylated gp140 and gp120 after 
PNGase F treatment (determined relative to the molecular weight marker), respectively. Blue arrows indicate 
the migration distance measured from the centre of the untreated Env band to the centre of the Endo H treated 
Env bands, either gp120 or uncleaved gp140. The plus sign (+) represents 30 ng of recombinant purified HIV-1 
gp120 (IIB-CHO from the AIDS reagent programme). The minus sign (-) represents the negative control for the 
purification of the Env from the growth medium of HEK 293T cells expressing the empty vector, pcDNA3.1 V5-
His Topo® (Invitrogen®). The PageRuler Prestained Protein Ladder (Thermo Scientific) molecular weight ladder 
is indicated in kilo Daltons (kDa) and used as a standard curve to determine the molecular weight of untreated, 
demannosylated and deglycosylated gp140 and gp120. A representative of three independent experiments is 
shown. 
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72 
 
weight between untreated and PNGase F-treated gp140 and untreated and PNGase F-treated 
gp120. N-glycosylation contributed 77kDa and 70kDa to the molecular weight of WT gp140 
and gp120, respectively. Similarly, to determine the percentage of high mannose residues 
present246, the difference in apparent molecular weight between untreated gp140 and gp120 
and corresponding Endo-H digested gp140 and gp120 were determined (Table 3.1).  
 
Table 3.1: Predicted and apparent molecular weights of gp140 wild-type and mutants after 
endoglycosidase treatments 
Env 
construct 
Molecular weight (kDa) of Envs* 
gp140 gp120 
Predicted Apparent 
(Untreated) 
Apparent 
(Endo H) 
Apparent 
(PNGase 
F) 
Predicted Apparent 
(Untreated) 
Apparent 
(Endo H)  
Apparent 
(PNGase 
F) 
Wild type 77  153 (SD: 
5.3) 
138 (SD: 
2.9) 
87 (SD: 
9.6) 
58.6 139 (SD: 
3.6) 
120 (SD: 
1.9) 
66 (SD: 
0.2) 
Q12H 77 155 (SD: 
2.1) 
141 (SD: 
0.7) 
87 (SD: 
13.6) 
58.6 137 (SD: 
5.7) 
118 (SD: 
0.2) 
66 (SD: 
2.6) 
Q12A 77 150 (SD: 
1.1) 
134 (SD: 
2.1) 
88 (SD: 
12.2) 
58.5 134 (SD: 
2.1) 
118 (SD: 
0.2) 
65 (SD: 
1.9) 
T415I 77 152 (SD: 
4.5) 
148 (SD: 
3.4) 
85 (SD: 
11.9) 
58.6 136 (SD: 
0.2) 
119 (SD: 
0.5) 
67 (SD: 
0.9) 
 
 
 
 
 
 
After EndoH digestion, the apparent MW of WT gp140 and gp120 was reduced by ~16kDa 
and ~15kDa, respectively. When the percentage high mannose was calculated relative to the 
total molecular weight of N-glycans, mannosylation of gp140 and gp120 were 17% (SD: 5) and 
28% (SD: 10), respectively (Figure 3.12). When the level of mannosylation of the soluble Env 
constructs containing the Q12H, Q12A or T415I mutations was compared to WT, there was 
*The molecular weight of unglycosylated Env (gp140 and gp120) for CAP210 E8 Env constructs was predicted using  online tools 
(http://web.expasy.org/compute_pi and http://www.hiv.lanl.gov/cgi-bin/GENE_CUTTER/cutter.cgi). The apparent molecular weight of the 
Env proteins detected by SDS-PAGE corresponding to deglycosylated gp140 and gp120 were calculated using a standard curve from the 
PageRuler Prestained Protein Ladder (Thermo Scientific) molecular weight ladder. Apparent molecular weights tabulated are an average of 
three independent experiments. 
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no significant difference (p = 0.2292). Therefore, changes in the signal peptide at position 12 
and deletion of the PNG at position 413-415 did not influence Env-N-glycosylation.  
 
The molecular weights of cell-associated gp140 and gp140 in the culture medium were similar 
and we proposed that uncleaved protein carried mostly high mannose residues. Previously, 
our lab showed that cell-associated gp140 was deglycosylated with Endo H, suggesting it only 
carried high mannose residues (data not shown). Furthermore, another study showed that 
gp140, if not cleaved, was hyperglycosylated due to non-native processing235. We showed 
that Endo H digestion of secreted gp140 did not generate deglycosylated protein, suggesting 
that uncleaved gp140 in the culture medium did not only carry high mannose residues but 
also processed complex N-glycans (Figures 3.11 and 3.12). Considering that gp120 was 
derived from cleaved gp140, we expected it to have similar levels of mannosylation. However, 
gp120 was more highly mannosylated than gp140 potentially due to four PNG sites within the 
20kDa region of gp41 reported to carry complex N-glycans248. Therefore, the 11% difference 
in mannosylation between secreted gp140 and gp120 is likely due to the presence of 
additional complex N-glycans and not differences in processing.  
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3.2.7 Pseudovirion entry efficiency  
As deletion of the PNG413 in subtype C CAP210 E8 TF Env increased expression 3.5-fold, we 
wanted to determine whether it enhanced Env entry efficiency. The signal peptide signature 
mutants were analysed to determine whether Env entry efficiency was affected, potentially 
via a pathway that did not include enhanced Env expression. 
 
Pseudovirus (PSV) was generated by co-transfecting HEK 293T cells with CAP210 E8 constructs 
and the packaging vector, pSG3∆env or pNL4.3-R-E-luc+. PSVs were generated using these 
two different packaging vectors to control for the potential influence of other viral proteins.  
PSVs, normalised to equal p24 concentration was added to TZM-bl cells211. PSVs generated 
using pSG3∆env carrying His12 or Ala12 had significantly lower entry efficiency than WT 
(Figure 3.13A and B). When pNL4.3-R-E-luc+ was used to generate PSV, entry efficiency was 
only slightly lower and the difference between WT and mutants was no longer significant 
(Figure 3.14A and B). The loss of significance is likely due to the poor infectivity of the pNL4.3 
Figure 3.12: Percentage mannosylation of gp140 and gp120. Mannosylation, the level of high mannose residues 
relative to total N-glycans was calculated based on shifts in molecular weights of gp140 and gp120 after Endo H 
and PNGase F treatment. Shifts in molecular weight of gp140 or gp120 after Endo H treatment indicated the 
contribution of high mannose residues to the total molecular weight of the protein whereas shifts in molecular 
weight after PNGase F treatment indicated the molecular weight of total N-glycans. The ratio of molecular 
weight of high mannose relative to that of total N-glycans were calculated and expressed as a percentage 
mannosylation. WT (WT), Q12H, Q12A or T415I Envs (gp140 and gp120) are indicated by each bar. Each bar 
represents the mean high mannose N-glycan percentages representative of three independent experiments 
with standard deviations generated using GraphPad Prism™ 5 and analysed by a one-way ANOVA with Tukey’s 
post-test. 
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backbone-generated PSVs (Figure 3.13C) coupled with high variability between biological 
repeats (Figure A2). Up to 2-fold difference in WT entry was observed between two 
independent experiments using this backbone when RLUs at 250 ng/mL p24 were compared 
(Figure A2.A). We did not add any reagents to improve infectivity as differences between 
clones might have been masked by enhancing agents. The introduction of either a Histidine 
or an Alanine at position 12 reduced Env entry efficiency, suggesting that the presence of a 
Glutamine at this position is important for Env function. The entry efficiency of T415I PSV 
generated using both pSG3∆Env and pNL4.3-R-E-luc+ was significantly higher (2-fold) than 
WT (Figure 3.13C). The increase in entry efficiency observed for the T415I mutant might be 
due to the 3.5-fold and 3-fold increase in Env expression and secretion, respectively.   
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Figure 3.13: Entry efficiency of pseudovirus carrying the signal peptide subtype B Env transmission motif. 
Pseudovirions (PSV) were generated with A, B) pSG3∆env or C, D) pNL4.3-R-E-luc+ HIV backbone and signature 
(Q12H) or non-signature (Q12A) signal peptide and WT (WT) Env constructs. A, C) PSV were diluted to 50, 100, 
200 and 250 ng/mL p24 (x-axis) and used to infect TZM-bl luciferase reporter cells in triplicate in three 
independent experiments. A representative line graph is shown with error bars representing standard deviation 
of the three triplicate values. B, D) Relative light unit (RLU) values from three independent experiments were 
averaged at p24 concentration 250ng/ml with bar graphs showing change in entry efficiency relative to WT. 
Background RLU obtained from mock infection controls were subtracted from all values including WT, signal 
peptide mutants and the pNL4.3-R-E-luc+ HIV backbone only control. Graphs were drawn using GraphPad 
Prism™ 5 and the bar graph was analysed using a one-way ANOVA with Tukey’s post-test.  An asterisk indicates 
statistical significance (** < 0.01). 
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3.2.8 Entry efficiency of chimeric Infectious Molecular Clones 
In order to determine whether the subtype B transmission motifs influenced the entry 
efficiency of infectious molecular clones (IMCs), we compared the ability of chimeric IMCs 
expressing WT and mutant Envs (Section 2.8.2) to enter TZM-bl cells (Figure 3.15).  
Figure 3.14: Entry efficiency of pseudovirus carrying the PNG415 subtype B Env transmission motif.  
Pseudovirions (PSV) were generated with A, B) pSG3∆env or C, D) pNL4.3-R-E-luc+ HIV backbone with wild-type 
(WT) or Env lacking PNG413 (T415I). A, C) PSV were diluted to 50, 100, 200 and 250 ng/mL p24 (x-axis) and used 
to infect TZM-bl luciferase reporter cells in triplicate in three independent experiments. A representative line 
graph is shown with error bars representing standard deviation of the three triplicate values. B, D) Relative light 
unit (RLU) values from three independent experiments were averaged at p24 concentration 250ng/ml with bar 
graphs showing change in entry efficiency relative to WT. Background RLU obtained from mock infection 
controls were subtracted from all values including WT, T417I mutant and the pNL4.3-R-E-luc+ HIV backbone 
only control. Graphs were drawn using GraphPad Prism™ 5 and the bar graph was analysed using a one-way 
ANOVA with Tukey’s post-test.  An asterisk indicates statistical significance (* < 0.5; ** < 0.01). 
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Interestingly, IMC entry efficiency of the signal peptide mutants showed opposing trends 
when compared to PSVs. Q12H and Q12A showed a significant increase in entry (p = 0.0007) 
compared to WT IMC (Figure 3.15). On the other hand, the entry efficiency of T415I IMCs 
(Figure 3.15) and PSVs (Figure 3.14) were similar although the difference did not reach 
significance at the lower IMC titre. In Figure 3.14C difference in entry between T415I and WT 
only became apparent at the highest p24 concentration, suggesting that more robust 
differences would have been clearer at both higher PSV and IMC titres. However, we cannot 
exclude the impact of intrinsic differences between PSVs and IMCs such as incorporation of 
Env due to differences in molar ratios of Env:Gag whereby PSV Env levels might be much 
higher than Gag due to co-transfection of separate vectors249. Inter assay variation was less 
pronounced for IMCs (Figure A2.B) compared to PSVs (Figure A2.A). However, since entry 
could only be tested at a single p24 concentration, i.e. 50 ng/mL, it is possible that this may 
have masked any variation between biological repeats that may only become apparent at 
higher titres as with PSVs (Figure A2.A). 
 
 
Figure 3.15: Entry efficiency of chimeric IMCs carrying the subtype B Env transmission motifs. Infectious 
molecular clones (IMCs) were produced via yeast homologous recombination to insert WT, Q12H, Q12A and 
T415I Env into pCMV-PBS-LTR-NL4-3∆gp160/URA. The chimeric IMCs (pCMV-PBS-LTR-NL4-3∆gp160/URA + env) 
were produced in HEK 293T cells and used to infect TZM-bl luciferase reporter cells at 50 ng/mL p24. 
Background relative light units (RLU) obtained from a mock infection control were subtracted from each 
experimental value. Bar graph showing the average of three independent experiments with standard deviation 
were drawn using GraphPad Prism™ 5 and analysed by one-way ANOVA with Tukey’s post-test.  An asterisk 
indicates statistical significance (*** < 0.001). 
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Discussion 
A genetic bottleneck occurs during HIV transmission when only a single variant, the TF 
overcomes the  mucosal barrier in the genital tract to establish productive clinical 
infection5,176,177. Vaccines that elicit an immune response to TF Env might be able to prevent 
HIV-1 infection however the high diversity of Env makes it difficult to identify a target 
conserved in all variants. With the discovery that transmission involved a single variant, it was 
proposed that TFs might carry conserved motifs that provide them with an advantage during 
transmission. The identification of a conserved transmission motif might provide the perfect 
target for immunogen design250.  
 
In this study, the impact of His12 and PNG4138 on a subtype C TF variant were investigated.  
Sequence analysis of over 500 subtype C acute infection env sequences from the Los Alamos 
HIV database revealed that 77% had a Glutamine at position 12 of the signal peptide and 
PNG413 was present in 95% subtype C TF sequences analysed.  Therefore, CAP210 E8 was 
selected for this study as it represented the majority of subtype C env TF sequences. The 
apparent lack of subtype B transmission motifs in subtype C TFs would suggest that subtypes 
might have evolved alternative mechanisms for transmission. Furthermore, vaccines that 
target these motifs might be ineffective against subtype C viruses. Thus, the aim of this study 
was to characterise the subtype B transmission motifs in the context of a subtype C TF variant 
to determine whether they have the same effect on Env function as previously described. 
 
Previous studies have suggested that positively charged amino acids found within Env-SP 
influences the rate at which it is cleaved from the N-terminal end of the protein106,107. 
Therefore, the more positive the SP, the slower Env-SP would be cleaved, leading to 
accumulation within the ER and reduced protein trafficking through the various 
compartments of the Golgi apparatus107. When the positively charged amino acids of the Env-
SP were replaced with neutral ones, the expression and secretion of gp120 increased107. This 
was contrary to the findings of Asmal et al. (2011) who reported that when the positively 
charged Histidine was replaced with the neutral, Glutamine, expression decreased13. In our 
study the signal peptide of the subtype C TF Env had a net charge of +2, less than the charge 
of the subtype B Env-SP of the AA01 clone13 (Figure 3.4). By substituting the Glutamine with 
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a Histidine, Env expression should have increased according to Asmal et al. (2011) and 
Updahyay et al. (2018) or decreased according to Li et al. (1994). However, when the 
Glutamine was substituted with both Alanine and Histidine there was no significant difference 
in Env expression compared to WT (Figure 3.7), suggesting that the positive charge of 
Histidine did not have an effect on Env-SP cleavage and thus did not alter cell-associated levels 
of Env.  
 
When the natural signal sequence of gp120 was replaced, Herrera and colleagues (2000) 
found that by fusing the mature gp120 glycoprotein to the signal peptide of erythropoietin 
(EPO-SP) or that of the tissue plasminogen activator (t-PA-SP) higher amounts of gp120 were 
secreted. EPO-SP resulted in much higher secretion of gp120 than the t-PA-SP exchange135, 
confirming that signal peptides can influence the secretion of the same protein differently. In 
our study, gp140 carrying the Q12H and Q12A polymorphism showed no significant difference 
in secretion compared to the WT (Figure 3.8). However, as gp120 was not detected in cell 
lysates, we were unable to calculate cleavage using cell–associated gp160 like previous 
studies240. The lack of a transmembrane (TM) region might influence gp140 processing and 
cleavage as the TM of gp160 has been shown to be important for processing and intracellular 
trafficking, suggesting that recombinant gp140 could be processed differently as it lacked 
gp41251. Based on N-glycosylation analysis of secreted Env, gp140 was processed similarly to 
that of gp120, with high mannose making up only, on average, 20% of total N-glycans. This 
could suggest cleaved and uncleaved gp140 underwent the same N-glycosylation and thus 
passed through the same processing pathway. The low level of mannosylation, however does 
suggest that gp140 did not undergo trimerisation as virus associated Env has been shown to 
carry mostly high mannose residues137,248. 
 
Previously it has been shown that an increase in expression can  change the N-glycosylation 
profile of Envs from subtypes A, B and C, such that it comprises of predominantly 
oligomannose137,153,252 and that mutating the Env-SP enriched for g160 monomers carrying 
high levels of high mannose N-glycans131. The authors suggest that gp160 retention due to 
slowed Env-SP cleavage may overwhelm the processing machinery in the ER leading to 
incorrectly processed protein131. No difference in the percentage of high mannose N-glycans 
was observed for the Env signal peptide mutants compared to the WT. This is in contrast to 
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previous findings when the substitution of positively charged Arginine residues at position 12 
and 16 with uncharged Isoleucines resulted in subtype C viral like particle (VLP)-associated 
Env with predominantly high mannose N-glycans131. Even though CAP210 E8 was also subtype 
C, when the Glutamine residue at position 12 was substituted with either a charged Histidine 
or a non-polar Alanine, gp140 and gp120 were still poorly mannosylated. This suggested that 
position 12 in subtype C TF Env-SP is not important for N-glycosylation as it can accommodate 
positively charged, uncharged and non-polar residues. This was expected as the Env-SP 
mutants showed no significant difference in expression, or ER retention compared to WT, 
suggesting that ER processes were not altered by these mutations. However, cleavage of 
gp140 and secretion of gp120 was reduced for Q12A relative to WT suggesting that processing 
steps that occur later during trafficking of Env might be influenced by the presence of a small, 
non-polar amino acid residue at position 12 of the Env-SP. Overall, the presence of either 
Glutamine or Histidine at position 12 of Env-SP does not seem to affect the processing of Env. 
This conclusion supports the high frequency of Glutamine at this position in subtype C viruses. 
Our findings might differ from other studies because the impact of SP changes on Env 
processing and function might be dependent on the Env clone and/or cells used to express 
gp160 and gp140.  
 
Despite lack of changes in Env processing, we wanted to confirm whether the signal peptide 
mutants had similar entry efficiency to WT. There was a significant decrease in entry efficiency 
of pseudovirus carrying the signal peptide mutations, Q12H and Q12A. However, this 
difference was not as apparent when PSV was produced with the pNL4.3-R-E-luc+ HIV 
backbone, suggesting that either interactions with other viral proteins might be important or 
variation could be due to experimental error. The low level RLU produced by the pNL4.3 
backbone-generated PSVs (Figure 3.13C) coupled with the high variability between biological 
repeats, may have affected infectivity and thus statistical significance could not be reached. 
We did not add any reagents to improve infectivity as differences between clones might have 
been masked my enhancing agents. Furthermore, cleavage of Q12A gp140 was reduced with 
concomitant decrease in PSV entry efficiency however this relationship was not consistent as 
Q12H gp140 was cleaved similar to WT. Overall, these results suggest that Gln12 is important 
for Env function however the potential mechanism did not involve changed in Env expression, 
secretion or mannosylation. 
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Recently, another study mutated His12 to Glutamine, Arginine (R) and Tyrosine (Y) and 
reported that expression, incorporation into virus, and IMC infectivity were lowered 
compared to WT203, supporting the findings of Asmal et al. (2011). The authors state that 
alteration in the signal peptide altered N-glycosylation and antibody sensitivity203, supporting 
the hypothesis that the loss of His12 during chronic infection could facilitate immune 
escape13. When we compared, N-glycosylation between signal peptide mutants and WT, 
there were no changes in mannosylation. However, this could be due to sensitivity of the 
methodology as Upadhyay et al. (2018) only observed changes in N-glycosylation when using 
lectin-binding Western blotting and mass spectrometry analysis. Perhaps, using these more 
stringent methods might allow detection of changes in N-glycosylation of CAP210 E8 Q12H 
and Q12A. 
 
The decrease in entry efficiency of the Q12H and Q12A mutants was in contrast to previous 
findings in which infectivity was enhanced for PSVs and IMCs carrying the His12 
polymorphism13,203. Differences between the outcomes of the studies could be due to 
differences in methodology as Asmal et al. (2011) used Jurkat T-cell lines and we used HEK 
293T cells for expression analysis although Upadhyay et al. (2018) also used HEK 293T cells. 
Cell type has previously been suggested to influence cleavage efficiency240 and N-
glycosylation patterns253 of transiently expressed Env. Furthermore, although both studies 
used the pSG3∆env backbone and TZM-bl cells for the PSV entry assay, Asmal et al. (2011) 
co-transfected a molar ratio of 4:1 of pSG3∆env:Env whereas we used a molar ratio of 3:1. 
The use of differing ratios of plasmids during transfection could alter the amount of Env 
trimers incorporated into PSVs249,254 thereby altering infectivity89. PSVs equivalent to 250 
ng/mL, 200 ng/mL, 100 ng/mL and 50 ng/mL were used to infect TZM-bl cells and it was noted 
that apparent differences between mutants and WT were only detected at higher titers, 
suggesting that when PSV concentration was limiting, differences between Env clones are not 
detected. Asmal et al. (2011) also normalised to p24 concentration but did not report on the 
concentration and indicated change in entry efficiency relative to dilutions. As the authors 
detected significant differences across all dilutions, PSV titres were either much higher than 
ours or differences in trimer incorporation influenced PSV infectivity.  
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Based on the findings of Asmal et al. (2011), we expected an increase in PSV entry efficiency 
when we introduced His12 into our clone and hypothesised that this could translate into 
higher replicative fitness which would be advantageous during transmission. However 
recently it was suggested that low replicative capacity of transmitted variants could favour 
transmission as individuals progressed slower to disease and were asymptomatic for longer, 
increasing the probability of transmission276,277. The authors also suggested that their 
hypothesis would explain why subtype C variants that were less fit than other subtypes had 
high global prevalence. It is interesting to speculate that the absence of His12 plays a role in 
reducing the replicative fitness of subtype C transmitted variants whereas its presence 
enhanced the fitness of subtype B variants. However, when His12 was introduced within the 
signal peptide of our subtype C Env, PSV entry efficiency decreased suggesting that subtype 
C transmitted founders would have lower fitness and slower disease progression if it carried 
a His12 which would contribute to its increased probability of transmission. It is likely that 
subtype C viruses have evolved to lower fitness via evolutionary pathways distinct from that 
of subtype B so that His12 does not have the same effect on both subtypes. It is also important 
to consider that we used a subtype B backbone to generate pseudovirus and IMCs, so it is 
possible that interactions between subtype C Env and subtype B viral proteins influenced the 
effect of His12 on the viral fitness of our mutants.  
 
As PSV entry efficiency might not reflect viral infectivity, we generated IMCs carrying the 
signal peptide mutations using the pCMV-PBS-LTR-NL4-3∆gp160/URA vector. We 
hypothesised that as Env is found on the IMC backbone, we might eliminate the influence of 
molar ratios and differences in incorporation of trimers. IMCs214 generated from the signal 
peptide mutants showed a significant enhancement in entry of TZM-bl cells compared to WT 
(p = 0.0007). This was contrary to the decreased entry efficiency of Q12H and Q12A, 
irrespective of whether pSG3∆env or pNL4.3-R-E-luc+ was used to generate the pseudovirus. 
Therefore, when PSVs and IMCs were generated with the same parent backbone, they still 
differed in entry efficiency: PSVs (decreased) vs IMCs (increased), suggested that HIV 
backbones were not influencing IMC entry efficiency. However, we were able to detect 
differences in IMC entry efficiency at 50 ng/mL p24, a titre where we could not detect 
variation in PSV entry efficiency. Thus, variation in entry efficiency could be due to intrinsic 
differences between IMCs and PSVs as suggested by Louder et al. (2005) and Provine et al. 
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(2009) where relative amounts of Env incorporated and efficiency of cleavage differed 
substantially between the PSV and IMC systems in subtype A and B viruses, respectively249,255. 
This hypothesis was supported when comparing our data to that of Upadhyay et al. (2018) as 
mutated IMCs behaved similarly in both studies although these authors could only detect 
differences at low titre contrary to our findings. There were also inconsistencies between 
Asmal et al. (2011) and Upadhyay et al., (2018) as the H12R mutation increased infectivity in 
the one and decreased IMC infectivity in the latter. The authors suggest that this could be due 
to electrostatic interactions with the SRP203. Furthermore, substitutions of Tyrosine at 
position 12 of JRFL with Arginine and Glutamine reduced IMC infectivity, suggesting that 
different amino acids at position 12 have different effects dependent on clone and, in our 
case, subtype.  
 
In addition to Upadhyay and colleagues’ inconsistencies between mutants, Asmal et al. (2011) 
also showed that PSV with a Glycine at position 12 had entry efficiency similar to clones with 
the His12 motif and the authors suggested that there were alternative determinants of 
infectivity. However, both reports did not consider the effect of PNG413 on PSV infectivity. At 
least one clone had both His12 and PNG413 (Appendix, Figure A1) and had higher Env 
incorporation than a clone where His12 and an adjacent amino acid residue were deleted. 
Also, the REJO isolate had a PNG at position 412 which could also influence infectivity. It is 
possible that PNG413 impacted the Env expression, secretion and incorporation experiments 
however we could not compare sequence data in detail (i.e. presence or absence of His12 and 
PNG413) with phenotype as Asmal and colleagues did not report on the accession numbers 
of their sequences. We thus went on to investigate whether PNG413 could modulate Env 
expression and processing as well as PSV infectivity. 
 
Individual N-glycans have been identified to be important for Env folding256,257 and can 
influence the conformation of neighbouring N-glycans258. These conformational changes due 
to N-glycosylation of particular sites can influence interactions between the Env on the 
incoming virus and binding to CD4 receptors on target cells259. The loss of, or change, in a 
specific PNG has also been shown to have differential effects on infectivity based on the 
location and proximity to other sites due to changes in binding interactions241. For example, 
the V3 loop, which remains stable during co-receptor binding260, has been suggested to 
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determine the specificity of co-receptor binding based on the loss of a single PNG either on 
the loop or on a neighbouring region241. The way in which glycans proximal to CD4 binding 
sites are processed has also been proposed to influence how antibodies interact with this 
region261. Therefore, changes at a single PNG, can alter Env function. 
 
The loss of PNG413 was suggested to be associated with receptor binding interactions based 
on the proximity of this PNG in relation to the CD4 and CCR5 co-receptor binding sites 
determined by protein modelling8. In this study, the expression, secretion and PSV entry 
efficiency of the CAP210 E8 T415I mutant was significantly higher compared to WT. It is 
possible that the 3-fold increase in secretion and 1.5-fold enhancement of gp140 cleavage 
was due to the 3.5-fold increase in Env expression. Perhaps the presence of PNG413 enhances 
interactions with chaperones leading to faster translocation into the ER and processing in the 
Golgi. Increased expression of Env did not lead to changes in N-glycosylation of CAP210 E8 
T415I although as discussed before, this could be due to lack of assay sensitivity. Surprisingly, 
both WT and mutants were poorly mannosylated which was unlike the data reported by other 
studies131,137 which reported Envs comprised of 98% oligomannose glycans. However, the 
authors highlighted that glycosylation patterns of virion-associated and recombinant gp120 
differ which could have influenced our findings as gp140 might not be processed similarly to 
gp160 to form trimers.  
 
Pseudovirus carrying the T415I mutation showed a 2-fold significant enhancement in entry 
efficiency compared to the WT (Figure 3.14). This observation was expected as a significant 
increase in Env expression (Figure 3.7) and secretion (Figure 3.9) was also observed. However, 
IMCs carrying the T415I mutation showed only a moderate increase (1.3-fold) in entry 
compared to its WT counterpart. This could be due to variation between PSVs and IMCs 
previously discussed (and illustrated in Figure A2). As this PNG occurs near the CCR5 co-
receptor binding domain8, it is possible that the enhanced infectivity observed for this mutant 
may be as a result of enhanced receptor affinity262. However, these findings need to be 
confirmed by measuring the incorporation of gp120 on the surface of pseudovirus as well as 
the measurement of binding affinities to receptors found on target cells, namely CD4, CCR5 
and DC-SIGN. Since the densities of CD4 and CCR5 on TZM-bl cells are not the same as the 
virus would encounter on target cells, it is also important to compare this entry efficiency 
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data to entry into a different cell line such as 293-Affinofile cells in which the expression of 
these receptors on the cell surface can be stimulated by hormones263,264 and thus the number 
of CD4 and CCR5 presented on the surface of these cells can be controlled.  
 
Conclusion 
Our study indicated that the subtype B transmission motifs were important for subtype C 
infectivity however the importance of the identity of the amino acid residue at positions 12 
and 415 or presence and absence of PNG413 varies between variants and subtypes. Although, 
we cannot exclude that assay differences contributed to inconsistent findings the influence 
of Glutamine at position 12 clearly had a positive influence on CAP210 E8 fitness whereas, 
across two studies, this particular residue termed as “non-signature” negatively influenced 
viral infectivity. Furthermore, all studies, including ours, did not consider the combined effect 
of His12 and PNG413 and we should thus have included double mutants in order to 
investigate the potential effects of the presence both subtype B TF transmission motifs on our 
subtype C TF clone. Despite these considerations, subtype C fitness is not dependent on a His 
at position 12 nor a PNG at 413. It is interesting to speculate that PNG413, which seems to 
have a fitness cost, is found in subtype C TFs because it provides a specific advantage to 
transmission such as enhancing Env interactions with DC-SIGN or α4β7. During chronic 
infection, PNG413 is lost as it improves replicative capacity and might also facilitate immune 
escape.  
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CHAPTER 4: IMPACT OF SUBTYPE B TRANSMISSION MOTIFS 
ON SUBTYPE C REPLICATION 
 
4.1 Introduction 
Changes in the signal peptide and a potential N-glycan site within gp120 altered the entry 
efficiency of PSVs and IMCs (Chapter 3). Although, previous studies have consistently used 
pseudovirus-based assays to measure Env functionality, these assays are performed using cell 
lines and can only measure a single round of replication. For this reason, a system which 
supports and measures replication over multiple rounds of infection might better resemble 
in vivo viral replication. We therefore constructed chimeric infectious molecular clones (IMCs) 
carrying CAP210 E8 WT and mutants in the context of a full HIV-1 proviral backbone65,249 and 
measured replication in peripheral blood mononuclear cells (PBMCs)265,266.  
 
The amplification of the env gene is the first step in the generation of chimeric infectious 
molecular clones (IMCs) using the yeast gap-repair system213. This involves the homologous 
recombination of PCR-amplified env DNA with a linearised proviral vector lacking the env, 
pCMV-PBS-LTR-NL4-3∆env/URA3214 via short sequences of homology in both DNA fragments. 
Homologous recombination should then result in the generation of a full-length viral genome 
to produce replication competent recombinant viruses. 
 
Homologous recombination is a natural mechanism that is used by yeast cells to repair their 
chromosomal DNA using regions of homology between the damaged DNA and the 
chromosome in order to repair the gap267. The yeast gap-repair method offers several 
advantages over the bacterial cloning in that it is efficient and uses both positive and negative 
selection markers to ensure the insertion of the env gene in the correct orientation268–270.  
This method supersedes standard cloning methods which rely on restriction enzyme 
digestions, gel purifications, in vitro ligations, and screening of the inserts in order to produce 
infectious full-length proviral DNA vectors214.  The subtype B backbone pCMV-PBS-LTR-NL4-
3∆env/URA3 used in these homologous recombination experiments was derived from the 
pREC_nfl_HIV-1∆env/URA3 plasmid in a series of cloning steps214. To generate the pCMV-PBS-
LTR-NL4-3∆env/URA3 backbone, the 5’LTR was replaced with a cytomegalovirus (CMV) 
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promoter in order to prevent recombination of the entire HIV genome. Thus the expression 
of the HIV genes is under the control of this promoter.  The env gene was replaced by the 
ura3 gene, which encodes the orotidine-5’phosphate decarboxylase protein (URA3) which is 
involved in the biosynthesis of uracil.  The plasmid also contains the beta-isopropylmalate 
dehydrogenase gene for the biosynthesis of leucine (LEU), an autonomously replicating 
sequence (ARSH4), and the yeast centromere sequence (CEN6), which all enables the 
recombinant plasmid to be cultured in yeast cells213.   
 
After successful amplification of the env gene of interest, the PCR product is co-transformed 
with the proviral backbone pCMV-PBS-LTR-NL4-3∆env/URA3 for homologous recombination 
in yeast cells. Colonies are then grown on negative selection medium. This medium contains 
5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidine carboxylic acid (FOA) which inhibits the 
growth of yeast which have not replaced the ura3 with env by homologous recombination. 
Yeast cells still containing the pCMV-PBS-LTR-NL4-3∆env/URA3 with ura3 will produce the 
URA3 enzyme which uses FOA to produce a toxic by-product 5’fluorouracil. Surviving colonies 
are then screened by PCR for the presence of the env gene as well as direct DNA sequencing 
for confirmation of full-length chimeric IMC vector for the production of replication 
competent viruses. Clones with the highest entry efficiency in TZM-bl cells are then selected 
to compare replicative capacity of these viruses in PBMCs. 
 
4.3 Results 
4.3.1 Amplification of the env gene from CAP210 E8 constructs 
In order to generate chimeric IMCs carrying the env sequence of interest, the yeast gap-repair 
system was used213,214. The first step in this assay was the amplification of the CAP210 E8 TF 
env constructs using primers designed to include flanking regions homologous to the IMC 
backbone to facilitate recombination in yeast cells.   
 
Optimisation of the PCR reaction included the use of various DNA Polymerases in order to get 
sufficient amplification of the env gene from the CAP210 E8 TF env constructs. The first of 
these optimisation steps was a comparison of the efficiency of the KAPA High Fidelity Taq 
Polymerase (KAPA Biosystems®) and Phusion (Thermo Scientific).  
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Wild-type (WT) CAP210 E8 env clone and the HIV-1pNL4.3 proviral vector (PNL4) were used as 
positive controls for the PCR amplification of the env gene. As we were introducing the native 
pNL4 env back into the pNL4.3 vector, we planned to compare this to the replication capacity 
of HIV-1pNL4.3 provirus as these two constructs should be similar. Template DNA at 5ng and 50 
ng were tested, and KAPA High Fidelity Taq polymerase appeared to yield a PCR product at 
both of these concentrations with the 50ng lane containing a more intense band than that of 
5 ng. No product was observed for the 5 ng template controls using Phusion polymerase 
however non-specific bands were observed at 50 ng. In an attempt to minimise these non-
specific bands, a gradient of template concentrations were used in order to amplify env from 
the WT. Again, non-specific bands were observed across all concentrations tested and this 
polymerase was thus excluded from all further optimisation steps (Figure 4.1).   
Figure 4.1: PCR amplification of env using KAPA High Fidelity Taq and Phusion polymerases. Complimentary 
primers flanked by short sequences of homology to the pol and 3’LTR, were used to amplify env from wildtype 
(WT) CAP210 E8 TF and the HIV-1pNL4.3 full-length proviral backbone (pNL4). (A) The KAPA High Fidelity Taq and 
Phusion DNA polymerases were tested for their ability to amplify env from WT and pNL4 at concentrations of 
5ng and 50ng. (B) A gradient of WT template concentrations (5, 12 and 15 ng) were tested using the Phusion 
polymerase to reduce non-specific bands during env amplification. Five microliters of each of the PCR products 
were visualised on a 0.8% ethidium bromide stained agarose gel. M indicates the DNA molecular weight ladder. 
 
A B 
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Since the KAPA High Fidelity DNA polymerase yielded no non-specific PCR products for the 
WT and pNL4 samples (at 5ng and 50ng starting template), it was used to amplify the env 
gene from the other CAP210 E8 constructs namely, the signal peptide mutants Q12H and 
Q12A, and the N-glycan mutant T415I. A single non-specific band was observed at ~1250 bp 
for the WT and Q12H samples (Figure 4.2A). No non-specific bands were observed for the 
other env PCR products however, when multiple reactions were pooled and run on an agarose 
gel, non-specific bands were observed consistently across all samples (Figure 4.2B). No PCR 
product representative of the env band was observed for the T417I mutant. Due to these 
findings we switched to Platinum High Fidelity Taq  (Invitrogen®). 
 
Figure 4.2: PCR amplification of env using the KAPA High Fidelity Taq polymerase. (A) The KAPA High Fidelity 
Taq polymerase (KAPA Biosystems®) was used to amplify env from wildtype (WT), signal peptide mutants (Q12H 
and Q12A), N-glycan mutant (T415I) and pNL4. (B) Multiple PCR products were pooled to purify the env band 
from the agarose gel. PCR products were visualised on a 0.8% ethidium bromide stained agarose gel for the 
presence of a ~3 kb band. 
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Platinum High Fidelity Taq polymerase PCR products yielded a single band for all env 
constructs that coincided with the expected size of env (Figure 4.3). However, direct DNA 
sequencing showed a number of PCR-derived insertions and deletions which would have 
rendered IMCs generated using these env amplicons, non-functional. Our final alternative 
DNA polymerase was the Q5 High Fidelity kit (New England Biolabs®). 
 
Initial optimisation of the PCR using the Q5 polymerase was at the DNA template 
concentration level as previous PCR experiments yielded non-specific bands when template 
concentrations were too high (data not shown). The optimal DNA template concentration was 
found to be 1 ng, however the primer concentrations needed to be optimised based on the 
ratio of template DNA to primers available for env amplification (Figure 4.4). 
 
Figure 4.3: PCR amplification of env using Platinum High Fidelity Taq polymerase. The Platinum High Fidelity 
Taq polymerase (Invitrogen®) was used to amplify env from wildtype (WT), signal peptide mutants (Q12H and 
Q12A), N-glycan mutant (T415I) and pNL4. PCR products were visualised on a 0.8% ethidium bromide stained 
agarose gel for the presence of a ~3 kb band. 
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Using WT DNA as the template, a gradient of primer concentrations were tested based on the 
recommended concentration of 0.5 µM. The optimal primer concentration was 0.2 µM as it 
yielded the most dense env band. This primer concentration was then used for all subsequent 
env PCR amplifications with 1 ng template DNA (Figure 4.5). 
 
 
 
Figure 4.4: Q5 High Fidelity polymerase primer concentration optimisation. A gradient of primer 
concentrations (0.5, 0.4, 0.3 and 0.2 µM) were tested to amplify wildtype (WT) CAP210 E8 TF env using Q5 High 
Fidelity polymerase (New England Biolabs®). Five microliters of each of the PCR products were visualised on a 
0.8% ethidium bromide stained agarose gel. M indicates the DNA molecular weight ladder. 
 
Figure 4.5: PCR amplification of env using Q5 High Fidelity polymerase PCR after primer concentration 
optimisation. Primer concentrations at 0.2 µM were used to amplify env from wildtype (WT), signal peptide 
mutants (Q12H and Q12A), N-glycan mutant (T415I) and pNL4 with the Q5 High Fidelity polymerase (New 
England Biolabs®). PCR products were visualised on a 0.8% ethidium bromide stained agarose gel. 
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The Q5 polymerase yielded PCR products for all env constructs. A band of ~3 kb was observed, 
with the env amplified from the pNL4 construct yielding the most intense band. Multiple PCR 
products were pooled and purified as described (Section 2.7.1) in preparation for 
transformation of yeast cells for homologous recombination with the linearised pCMV-PBS-
LTR-NL4-3∆gp160 URA backbone.  
 
4.3.2  Screening yeast for homologous recombination by colony PCR 
In order to generate chimeric IMC backbones carrying the env gene of interest, the env 
amplicon was co-transformed with the shuttle vector pCMV-PBS-LTR-NL4-3∆env/URA3 into 
competent S. cerevisiae cells and grown on negative selection minimal medium deficient of 
Leucine and in the presence of 5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidine carboxylic 
acid (FOA). Cells which have replaced the ura3 with env in the pCMV-PBS-LTR-NL4-
3∆env/URA3 vector formed colonies in the presence FOA. Colonies were screened by PCR for 
the presence of the env gene (Figure 4.6). Primers complimentary to a region spanning 
positions 237 to 585 (HXB2 numbering) within the env were used in colony PCR to generate a 
band of 1 kb. Of the twenty-five colonies tested (five per env construct), twenty carried the 
env gene insert (Figure 4.6). The sizes of the PCR products were higher than the expected 1 
kb due to the presence of the 5’ vpu-rev flanking region which is not always fully sequenced, 
therefore the exact length and identity is often unknown. 
 
 
 
 
 
 
Figure 4.6:  Screening yeast colonies for homologous recombination. Yeast cells were transformed with the env 
PCR product and linearised pCMV-PBS-LTR-NL4-3∆gp160/URA3 backbone. Yeast colonies were screened by 
colony PCR using FW-Env-Y and RV-Env-Y env-specific primers. Ten microliters of the reaction was separated on 
a 0.8% agarose gel. PCR products of a yeast colonies that have replaced the ura3 gene with the env amplicon 
are indicated by a band at ~1 kb and the water control (contamination control) indicated by a minus sign, 
respectively. A line indicates the lanes with screened colonies. M indicates the DNA molecular weight marker. 
T415I 
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4.3.3 Testing functionality of chimeric viruses using entry efficiencies into TZM-bl cells 
Once colonies that carried chimeric IMC DNA were identified, plasmid was prepared and 
HEK293T cells were co-transfected with the IMC construct and the pCMV_NL4-3LTR-Gag4 
(helper plasmid) to generate chimeric virus. Chimeric IMCs were used to infect TZM-bl cells 
and those that generated luminescence readings 2.5 times higher than background were 
regarded as carrying functional Env. Only clones with the highest fold change were selected 
for further analysis (Table 4.1). However, as chimeric viruses were not normalised prior to 
infection of TZM-bl cells, factors other than IMC fitness could be contributing to increased 
entry such as transfection efficiency and quality of plasmid DNA. Clones were then sent for 
full env sequencing (Section 2.2.5) to verify the presence of the env gene and that no PCR-
derived mutations were present (data not shown).  
 
Table 4.1 Infection of TZM-bl cells by chimeric IMCs to determine functionality. 
 WT 
clone 2 
Q12H 
clone 5 
Q12A 
clone 4 
T415I 
clone 5 
pNL4 
clone 2 
HIV-
1pNL4.3α 
pCMV-PBS-LTR-
NL4∆gp160/URA#  
Average RLU* 349663 475957 437668 352613 627138 7701954 15461 
Fold-change# 22.61 30.78 28.30 22.81 40.56 498.17 1.00 
Functionality# Yes Yes Yes Yes Yes Yes No 
 
 
 
 
 
 
4.3.4 Testing donor PBMCs that can support replication of HIV-1pNL4.3 
After isolation of PBMCs from blood (Section 2.8.1), three different donors were tested for 
their ability to support the replication of HIV-1pNL4.3 virus. We selected, HIV-1pNL4.3 as despite 
it being X4-tropic as it was previously shown that CD4+ T cells infected with R5 variants 
produced more progeny than HIV-1pNL4.3 when PHA and CD3/CD28 antibodies were used to 
stimulate PBMCs. We thus rationalised that if HIV-1pNL4.3 replication was detectable under 
those conditions then our R5 chimeric Env IMCs would be too275. Virus was harvested 4, 7 and 
10 days post-infection. p24 ELISA of day 10 harvests showed that donors 1 and 2 could 
support replication of HEK 293T cell-produced HIV-1pNL4.3 virus as these gave the highest p24 
values of 373 ng/mL (SD: 157.59) and 300 ng/mL (SD: 163.07), respectively (Figure 4.7).  
 * Functionality of chimeric IMCs was tested by infecting TZM-bl cells with HEK 293T cell culture supernatant containing virus 
in duplicate and calculating the average relative light units (RLU) determined using a luciferase reporter assay.  
# To determine functionality, the RLU obtained from duplicate wells was divided by the RLU obtained from the mock infection 
(pCMV-PBS-NL4∆gp160/URA only) and indicated as fold-change above background. Functional (Yes) or non-functional (No) 
clones are indicated if the fold background was greater or less than 2.5, respectively.   
α HIV-1pNL4.3 was used as a positive control.  
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4.3.5 Replication of expanded IMCs using donor PBMCs 
Since HEK 293T cell-produced IMCs gave poor Tissue Culture Infectious Dose 50 (TCID50) 
values (Table 4.2), these virus stocks were expanded in the two donor PBMCs identified to 
support replication (Section 2.8.6; Section 4.2.4) and TCID50 assays212 performed 7 and 10 
days post-infection. . It was found that expansion either improved or decreased TCID50/mL 
values whereas there was no change for some. The variation depended on donor with most 
TCID50 values lower after expansion in donor 1 compared to donor 2. There was also no 
consistent increase in TCID50 values with increase in days post-infection (dpi) (Table 4.2). As 
expected, the positive control, HIV pNL4.3 provirus had higher TCID50 than the other variants. 
Due to the low IMC titre, all harvests were pooled, concentrated using ultracentrifugation 
(Section 2.8.5) and then used to infect activated donor PBMCs at 100 TCID50 units. 
 
 
 
 
Figure 4.7:  Pilot replication assay to test donor PBMCs using HIV-1pNL4.3. Virus produced in HEK 293T cells was 
used to infect three different activated donor peripheral blood mononuclear cells (PBMCs) with HIV-1pNL4.3 in 
triplicate. Virus supernatant was harvested 4, 7, 10 and 14 days post-infection. A bar graph showing the mean 
p24 ELISA concentrations (ng/mL) 10 days post infection with error bars indicating the standard deviations 
between triplicate values was generated. Virus only controls were included in order to show the initial viral 
titres.  
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Table 4.2: TCID50 values using TZM-bl infectivity assay of virus before and after viral 
expansion in PBMCs 
Chimeric virus ID TCID50/mL* 
Before expansion After expansion 
PBMC Donor 1 PBMC Donor 2 
7 dpi 10 dpi 7 dpi 10 dpi 
WT 0 0.0905 0 1.77 0 
Q12H 2.15 1.77 0.0905 1.77 0 
Q12A 3.16 1.77 0.0905 0.0905 0 
T415I 0 1.77 0.0905 4.64 1.77 
pNL4 3.16 0.0905 0 2.15 1.77 
HIV-1pNL4.3 3.16 1.77 2.15 3.16 1.77 
 
 
 
We expected pNL4 IMC (pCMV-PBS-LTR-NL4-3∆gp160/URA vector + pNL4 env) and the 
proviral HIV-1pNL4.3 to replicate to similar levels in PBMCs. However, this was not the case as 
HIV-1pNL4.3 yielded higher TCID50/mL values in both donors than the pNL4 IMC. Overall, IMCs 
appeared to have expanded/replicated better in PBMCs isolated from Donor 2 than from that 
of Donor 1 as TCID50 measurements were higher 7 dpi. After ultracentrifugation, the TCID50 
measurements (Table 4.2) improved by around 5-fold (data not shown) however they were 
still quite low even after pooling and infections were therefore carried out using 100 TCID50 
units of virus as opposed to the 300 TCID50 units used during the pilot study (Sections 2.8.7 
and 4.2.4). Replication was monitored over 2 weeks and virus supernatants harvested 4, 7, 10 
and 14 days post infection and virus titres quantified by p24 ELISA. However day 4 harvests 
showed no detectable levels of p24 protein (data not shown) and was therefore excluded. 
The average p24 concentrations (ng/mL) between the two donors for each virus were plotted 
over time (Figure 4.8A), since the overall trend between the two donors were similar (Figure 
A3). The mean slope of these curves was also plotted as a bar graph271 (Figure 4.8B)  
 
 
 
 
 
 *TCID50/mL values were calculated using the method described by Reed & Meunch (1983) after infection of 
TZM-bl cells with serially diluted virus stocks205.   
dpi: days post-infection 
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The signal peptide mutant, Q12A, and the positive control HIV-1pNL4.3 were the only two IMCs 
to show detectable levels of p24 after ELISA (Figure 4.8) and thus a comparison between IMC 
entry efficiencies into TZM-bl cells versus replication of IMCs in PBMCs could not be made.  
 
4.4 Discussion 
Previous studies suggest that there are inconsistencies in the findings with regards to 
infectivity based on the viral expression system used even when the same producer cell line 
is used249,255. Discrepancies in results may also be due the comparison of entry efficiency data 
of pseudovirus which only undergoes a single round of replication versus that of infectious 
molecular clones (IMCs) which are replication competent. In order to address this issue, 
chimeric IMCs carrying the env of interest were generated using the yeast recombination 
assay213. Chimeric IMCs were then produced in HEK293T cells, expanded in peripheral blood 
mononuclear cells (PBMCs) and used to infect these cells in order to compare replicative 
fitness.  
            
      
Figure 4.8:  Replication of chimeric IMCs in PBMCs. PBMCs from two donors were infected with viruses with 
equal TCID50 generated from CAP210 E8. Viral replication was quantified by p24 ELISA on days 0, 7, 10, and 14 
post infection. (A) The mean p24 concentration from the two independent assays from 2 donors were plotted 
over time. Error bars represent the standard error of the mean. HIV-1pNL4-3 virus was used as positive control. (B) 
Mean slopes of p24 curves were calculated using the slopes between RLU values at days 0 and 7, 0 and 10, and 
0 and 14. Slope values for each virus was used to calculate the mean and standard deviation of two independent 
donors and used to generate a bar graph269 in GraphPad Prism™ 5. 
A B 
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In order to measure replicative capacity, env was shuttled into the pCMV-PBS-LTR-NL4-
3∆gp160/URA vector to generate recombinant viruses using the yeast gap repair system213. 
The first step in the generation of these full-length proviral vectors was the PCR amplification 
of the env gene from CAP210 E8. As part of a series of optimization steps in order to get PCR 
product, a range of DNA polymerases were tested including varying DNA template 
concentrations, primer concentrations and PCR run parameters. The Q5 High Fidelity Taq 
Polymerase was chosen as it yielded the desired ~3 kb product (Figure 4.5). Although larger 
non-specific bands were also present which could not be removed even after several 
troubleshooting runs, direct sequencing of the final IMC constructs showed that there were 
no additional PCR-derived mutations present (data not shown).  
 
Clones able to enter TZM-bl cells (Table 4.1) were taken forward to be produced at a larger 
scale in HEK 293T cells. When the TCID50 was determined for chimeric IMCs produced in HEK 
293T cells, they were found to be poor and thus virus could not be used to infect donor 
PBMCs. This may be due to the efficiency of transfection due to the length of the vector272 
which ultimately affects the amount of virus particles the cells can produce. For this reason, 
we then expanded these HEK 293T cell-produced virus into in two different donor PBMCs 
(identified to support replication) to improve TCID50 measurements (Table 4.2). Even after 
viral expansion in PBMCs, TCID50 values were still low and therefore virus was concentrated 
by ultracentrifugation and the used to infect activated donor PBMCs.  
 
When p24 ELISAs were performed on virus supernatants harvested over 14 days, detectable 
levels of p24 protein were only observed for the signal peptide mutant, Q12A, and the positive 
control HIV-1pNL4.3 (Figure 4.8). This may be due to the sensitivity of the ELISA although we are 
routinely able to detect virus at concentrations as low as 500 pg/mL. Furthermore, replication 
of HIV-1pNL4.3 provirus was not detected when it usually replicates to high titres (data not 
shown). Since the amount of TCID50 units used for the infection was reduced from 300 to 
100, it may be possible that the multiplicity of infection (MOI) was too low for productive, 
detectable infection. As possible T lymphocyte quiescence was a concern and HIV 
preferentially targets activated CD4+ T lymphocytes273, IL-2 was used to stimulate cells274 and 
was replenished after each harvest273. However, the decrease in replication after 7 days 
suggests that activation might not have been optimal and that PBMCs were dying over time. 
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Cytopathic events have been shown to limit replication in PBMCs although HIV-1pNL4.3 has 
been shown to be less pathogenic than other variants275. However as the Env might have 
impacted the cytopathic nature of HIV-1pNL4.3 we should have tested cell viability during and 
after replication of chimeric IMCs to determine whether the PBMCs remained viable.  
 
Since replication was not observed for the Q12H and T415I mutants, we could not compare 
the entry of chimeric IMCs into TZM-bl cells to the replicative capacity in PBMCs. Other clones 
of these chimeric IMCs which were identified during screening (Table 4.1) should be tested 
for their ability to replicate so that the effect of these motifs can be characterised based on 
infectivity in the context of replication competent virus. 
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CHAPTER 5: SUMMARY AND CONCLUSIONS 
 
In this study, the robust transmission motifs identified in subtype B TF Envs8 were investigated 
for their potential role in the expression, processing and infectivity of a subtype C TF Env from 
CAP210 E8. CAP210 E8 represented the consensus of subtype C TFs as it lacked the 
transmission motifs: it carried a Glutamine at position 12 (Gln12) and a PNG at position 413-
415. Site-directed mutagenesis successfully introduced the transmission motifs into CAP210 
E8 to generate signal peptide mutants, Q12H and Q12A as well as the PNG mutant T415I. Full-
length (gp160) and soluble (gp140) forms of these Env constructs were generated and 
expressed in HEK 293T cells for expression, secretion, cleavage efficiency and N-glycosylation 
analyses as well as the production of PSV to test infectivity of TZM-bl cells and chimeric IMCs 
for replication in donor PBMCs. 
 
Table 5.1 Overview of the phenotypes of signal peptide and N-glycan mutants relative to 
wild-type (WT) 
Mutant 
ID 
Expression Secretion Cleavage Mannosylation PSV entry 
efficiency 
IMC entry 
efficiency 
pSG3 pNL4.3 pNL4.3 
Q12H 0 0 0 0 <* 0 >* 
Q12A 0 < < 0 <* 0 >* 
T415I >* >* >* 0 >* >* > 
* Difference was significant (p < 0.05) 
0: no change; >: increase; <: decrease relative to WT 
 
Referring to Table 5.1, it is evident that the loss of Threonine at position 415 and/or the loss 
of PNG413 enhanced CAP210 E8 infectivity most likely by altering expression. On the other 
hand, the analysis of the findings of the signal peptide mutants are more complicated as there 
were inconsistencies between mutants and between assays. Q12A had lower secretion and 
apparent cleavage than WT which correlated with the observed decrease in PSV entry 
efficiency. As secretion and apparent cleavage of Q12H did not change, this would suggest 
that it is the type of amino acid at position 12 that is important and not Histidine or charge. 
Gln12 is the preferred polymorphism for subtype C TF, and deletion of this amino acid results 
in loss of fitness. However, Q12H and Q12A IMCs could enter TZM-bl cells better than WT. 
This could suggest that in multiple rounds of infection, the presence of His12 is beneficial. 
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Furthermore, contrary to previous findings13,203, His12 did not enhance Env expression, 
processing and PSV infectivity. The increase in IMC entry efficiency was the only consistent 
finding between this study and earlier reports13,203. As Asmal and colleagues tested PSVs 
generated by pNL4.3 and Upadhyay et al. (2018) compared IMCs of REJO and JRFL isolates, it 
is unlikely that the HIV backbone, (pSG3 vs pNL4.3) and the assay (PSV vs IMC) was directly 
responsible for the differences between our study and theirs. We would like to suggest that 
the reason for the inconsistencies within our study is multifactorial that include protein-
protein interactions, cell type factors and assay conditions whereas differences between our 
study and earlier reports is due to subtype differences. It was very unfortunate that we were 
unable to measure and compare the replication of the chimeric IMCs in donor PBMCs as this 
might have shed light on the potential impact that different amino acids at position 12 might 
have on HIV-1 replication, a more physiologically relevant model. Therefore, future studies 
will include: optimising the replication assay, testing clones other than CAP210 E8, comparing 
incorporation of gp120 in PSVs and IMCs and determining N-glycosylation of PSV- and IMC-
associated Env using mass spectrometry.   
 
In conclusion, these findings suggest that position 12 of the Env signal peptide is important to 
subtype C and B HIV infectivity although the mechanism needs to be further investigated. 
However, the presence of Histidine at this site decreased CAP210 E8 fitness and that subtype 
C variants have evolved and selected for a Glutamine at this position most likely because it 
benefits viral survival. Similarly, PNG413 (or Thr415) is important for viral infectivity but as it 
is present in subtype C TFs and absent in subtype B variants, it also might have evolved to 
impact HIV-1 fitness in a subtype specific manner. This has serious implications for vaccine 
design as any selection pressure that drives the loss of His and/or PNG413 might enhance the 
viral fitness of diverse variants, resulting in increased disease progression.  
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APPENDIX I - SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
 
 
 
                                             
 
Figure A2: Entry efficiency of pseudovirus and IMCs shows high inter-assay variability. Using Wild type (WT) 
as an example, A) Pseudovirions (PSVs) generated with pNL4.3-R-E-luc+ HIV backbone were diluted to 0, 50, 
100, 200 and 250 ng/mL p24 and used to infect TZM-bl luciferase reporter cells in triplicate. The bars indicate 
the relative light unit (RLU) values generated with error bars representing standard deviation of the three 
triplicate values. Three biological repeats (BLR) show the variation between assays using PSVs that were 
generated using the same HIV backbone. B. IMCs were diluted to 50 ng/mL p24 and used to infect TZM-bl cells 
in triplicate. Bars show RLUs of three independent experiments with error bars indicating the standard deviation 
of the mean. 
Figure A1: Alignment of subtype B transmission motifs. CAP210 E8 sequence was aligned to subtype B 
sequences: HXB2 and five sequences analysed by Aslam et al. (2011) and REJO and JRFL analysed by Upadhyah 
et al. (2018). The putative transmission motifs, His12 and PNG413, are indicated by grey bars and the amino 
acids mutated in this study are indicated with arrows. The Histidine in the signal peptide is indicated as 
position 12 despite HXB2 numbering indicating that it is at position 9. Gnanakaran et al. (2011) indicated that 
the numbering of some positions was based on positions within alignments and not always HXB2 numbering. 
To avoid confusion, we selected to continue with numbering the His as position 12. The second transmission 
motif was identified as the Threonine at position 415 but as this amino acid determined the presence of a PNG 
at 413, the N-glycan site was considered to be important for transmission and thus we refer to PNG413 as the 
transmission motif and substituted T415 with an Isoleucine (I), the common amino acid found in this position, 
to delete the PNG8. HXB2 numbering was determined as explained at www.lanl.gov.  
 
A B 
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Figure A3:  Replication of chimeric IMCs in PBMCs from two different donors show similar trend. PBMCs from 
two donors were infected with viruses with equal TCID50 generated from CAP210 E8. Viral replication was 
quantified by p24 ELISA 0, 7, 10, and 14 post infection. The p24 concentration in ng/mL from the two 
independent assays from 2 donors were plotted on separate line graphs over time.  
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APPENDIX II - SOLUTIONS 
 
Plasmid DNA isolation and gel electrophoresis 
 
10X TBE 
108 g Tris-Cl 
55 g Boric Acid 
9.3 g EDTA 
Top up to 1 L with dH2O after adjusting pH to 8.5 with 10% citric acid 
 
6X DNA loading dye 
0.025 g Bromophenol Blue 
0.025 g Xylene Cyanol 
6 mL 50% glycerol  
4 mL dH2O  
 
0.8% agarose gel 
0.8 g agarose 
100 mL dH2O  
Add 2 µL EtBr after heating 
 
STET buffer 
8 g Sucrose 
5 g Triton X-100 
10 mL 0.5 M EDTA, pH 8.0 
5 mL 1 M Tris-Cl, pH 8.0  
Top up to 100 mL with sterile dH2O 
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SDS-PAGE and western blotting 
 
RIPA buffer 
10 mM Tris-Cl (pH 7.4) 
150 mM NaCl 
1% Sodium deoxycholate 
0.1% SDS 
1% Triton-X100 
Make up to 100 mL with dH20 
 
10X running buffer 
30.285 g Tris-Cl 
144.13 g Glycine 
10 g SDS 
Make up to 1 L with dH2O after adjusting pH to 8.3 with HCl 
 
5X protein loading buffer 
1 mL 1 M Tris-Cl (pH 6.8) 
2.5 mL 20% SDS 
4 mL 50% glycerol 
0.01 g Bromophenol blue 
Make up to 10 mL with dH2O  
 
Transfer buffer (TOWBIN) 
3.025 g Tris-Cl 
14.4 g Glycine 
200 mL Methanol 
Make up to 1 L with dH2O 
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8% resolving gel 
2 mL 30% Acrylamide/bis-Acrylamide 
2.8 mL 1M Tris-Cl (pH 8.8) 
37.5 µL 20% SDS 
40 µL 20% Ammonium persulphate 
20 µL TEMED 
2.56 mL dH2O 
 
7% stacking gel 
0.85 mL 30% Acrylamide/bis-Acrylamide 
0.625 mL 1M Tris-Cl (pH 6.8) 
25 µL 20% SDS 
30 µL 20% Ammonium persulphate 
10 µL TEMED 
3.46 mL dH2O 
 
Partial protein purification 
 
MES binding buffer 
6.5 mL 1 M NaCl 
5 mL 100 mM CaCl2 
10 mL 100 mM MES monohydrate 
Make up to 50 mL with dH2O after adjusting pH to 6.0 with HCl 
 
1X MMP competitive binding buffer 
9.709 g MMP 
Make up to 50 mL with 1X PBS 
 
1X PBS wash buffer 
150 µL 100 mM CaCl2 
245 µL 100 mM MgCl2 
49.71 mL 1X PBS 
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Coomassie stain 
50 mL Methanol 
10 mL Glacial acetic acid 
1 g Coomassie Brilliant Blue R-250 
Make up to 100 mL with dH2O 
 
Destaining solution 
125 mL Ethanol 
50 mL Glacial acetic acid 
Make up to 500 mL with dH2O 
 
Yeast gap repair assay 
 
YEPD media 
10 g Yeast Extract 
20 g Peptone 
20 g Dextrose  
Make up to 1 L with dH2O 
Mix and autoclave. 
 
Yeast Dropout media 
6.7 g YNB (Yeast Nitrogen Base) 
20 g Dextrose 
Make up to 1 L with dH2O 
Stir until completely dissolved and autoclave 
 
Yeast Amino Acid Dropout plates + FOA 
Add 20 g agar 
Add 6.7 g YNB (Yeast Nitrogen Base) 
20 g Dextrose 
0.69 g CSM-Leu 
1 g FOA  
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Make up to 1 L with dH2O 
Stir until completely dissolved, autoclave and pour 
 
10X TE Buffer 
10 mL 1M Tris-Cl (pH 8.0) 
2 mL 0.5M EDTA (pH 8.0) 
Make up to 1 L with dH2O 
 
Replication assay  
 
Full RPMI 
Remove 60 mL RPMI from the bottle and add the following: 
50 mL FBS 
10 mL Pen/Strep 
(Supplement with IL-2 and/or pHA, if necessary) 
